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Many neurological diseases present with comorbid gastrointestinal (GI) abnormalities, 
suggesting parallel altered functionality of the central nervous system (CNS) and enteric 
nervous system (ENS). A potential mechanistic link between CNS and GI disorders is 
aberrant function of voltage-gated sodium channel (VGSC) a and b subunits, which are 
expressed in both CNS and ENS. VGSCs control the generation and propagation of 
action potentials in neurons and therefore play a critical role in neuronal excitability and 
signaling. VGSC b1/b1B subunits, encoded by SCN1B, modulate ion channel expression, 
trafficking, gating, and voltage-dependence. VGSC gene variants are linked to 
developmental and epileptic encephalopathies (DEEs) and GI motility disorders. 
Additionally, DEE patients with VGSC – and other voltage-gated ion channel (VGIC) gene 
variants – often exhibit chronic constipation. The overall goal of my PhD thesis research 
was to test the hypothesis that aberrant activity or expression of VGICs contributes to the 
mechanism of GI dysfunction in the Scn1b-null mouse model of DEE. The first research 
project contained in this thesis investigated GI symptoms among patients with DEEs 
linked to variants in VGIC genes in an effort to identify commonalities between patients 
exhibiting GI symptoms. We found that GI symptoms are prevalent and often severe in 
DEE patients and are not fully explained by factors often implicated in GI dysfunction, e.g. 
functional mobility, diet, or medications.  By focusing on DEE patients with variants in 
genes encoding VGICs, these results highlight the need to better understand the role of 
 xi 
aberrant function of voltage-gated ion channels that may directly contribute to the 
observed GI pathology. 
 
The second portion of my thesis research investigated a functional role of VGSC β1/b1B 
subunits in GI motility. A subset of DEE patients has biallelic loss-of-function variants in 
SCN1B. In addition to aberrations in neuronal firing within the CNS, multiple physicians 
report SCN1B-linked DEE patients presenting with GI symptomology, including 
constipation. The objective of this project was to understand how b1/b1B subunits 
contribute to GI function using a Scn1b-null mouse model.  Our results indicate that 
b1/b1B are involved in maintaining proper frequency and regularity of colonic 
contractions, likely via transcriptional regulation of voltage-gated ion channel expression.  
 
Taken together, the results of my thesis work shed light on the prevalence and potential 
causes of GI symptoms in VGIC-linked diseases, including DEE, and provide a 
mechanistic role for SCN1B in colonic motility. 
 1 
Chapter 1 : Introduction 
 
 
1.1 A Proposed Mechanism for the Gut-Brain Disease Connection 
 
 
There is a growing body of evidence suggesting a significant connection between central 
nervous system (CNS) and gastrointestinal (GI) dysfunction. Specifically, clinical studies 
have reported high incidences of bowel dysmotility in patients with multiple forms of 
epilepsy as well as neurological epilepsy comorbidities, such as autism spectrum 
disorders, depression, anxiety, and multiple sclerosis (Bassotti et al., 1998; Gershon, 
2005; Gorard, Gomborone, Libby, & Farthing, 1996; Mazurek et al., 2013; Nordenbo, 
Andersen, & Andersen, 1996; Norton & Chelvanayagam, 2010; M. Rao & Gershon, 2016; 
Winge, Rasmussen, & Werdelin, 2003). Likewise, neuronal mechanisms have been 
implicated in GI diseases often characterized by constipation, such as irritable bowel 
syndrome (IBS), which is thought to be partially caused by altered activation of enteric 
neurons, and Hirschsprung’s disease (HSCR), which is caused by an absence of neurons 
in distal bowel (Gershon, 2005; O'Donnell, Coyle, & Puri, 2016). The large degree of 
overlap between CNS and GI disorders suggests one or more mechanistic links between 
these two physiological systems in disease states. One potential explanation for co-
manifestation of CNS and GI symptoms is a shared cause of neuronal dysfunction in 
these two organ systems, and the goal of my thesis work was to investigate one such 
candidate mechanism: aberrant voltage-gated sodium channel (VGSC) function.  
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VGSC-associated gene variants are linked to multiple neurological diseases, including 
developmental and epileptic encephalopathies (DEEs) (Aeby et al., 2019; Chahine, 
Chatelier, Babich, & Krupp, 2008; Kaplan, Isom, & Petrou, 2016; O'Malley & Isom, 2015). 
Notably, chronic or severe constipation is reported in multiple case studies of DEE 
patients with variants in VGSC and other voltage-gated ion channel (VGIC)-encoding 
genes (Table 1.1) as well as patients with variants in FHF1, which encodes a fibroblast-
growth-factor homologous factor that is known to modulate VGSC inactivation (Al-
Mehmadi et al., 2016; Berecki et al., 2018; de Kovel et al., 2014; Leipold et al., 2013). 
Furthermore, variants in the VGSC-encoding genes SCN5A and SCN11A have been 
linked to GI pathologies, such as IBS and HSCR (Neshatian et al., 2015; O'Donnell et al., 
2016; Saito et al., 2009; Strege et al., 2018; Woods, Babiker, Horrocks, Tolmie, & Kurth, 
2015). These clinical findings show that variants impacting VGSC function often produce 
both neurological and GI symptomology. 
 
The studies contained in this thesis investigate the role of VGSCs – and specifically their 
b subunits – in GI function and dysfunction. Chapter 1 provides a background on the 
established physiological functions of VGSCs and their b subunits, the organization of the 
enteric nervous system, the different patterns of GI motility, and the previously known 
roles of VGSCs in the GI tract. Chapter 2 focuses on the clinical presentation of GI 
symptoms in patients with channelopathy DEEs and explores potential causative factors 
in this population. Chapter 3 presents experiments that interrogate the role of VGSC b 
subunits in enteric nervous system development and function in a mouse model of 
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channelopathy DEE. Chapter 4 discusses future avenues of research that may reveal 
additional functions of VGSC b subunits in GI and gut-brain-axis function. Overall, these 
findings suggest that VGSC b subunits are critical for the coordinated signaling of enteric 
neurons and proper functioning of the GI tract. 
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IN HUMAN GI TRACT 
KNOWN GI SYMPTOMS 
ASSOCIATED WITH 
GENETIC VARIANT  
SCN1A (NAV1.1) OMIM DEE6 (Claes 
et al., 2001; Dravet, 
2011) 
Colonic MP, colonic 
mechanosensitive nerve 
fibers (Hetz et al., 2014; 
Osteen et al., 2016) 
Appetite disturbances, 
constipation, intestinal 
dysmotility (Beck, Isom, & 
Berg, 2021; Villas, Meskis, 
& Goodliffe, 2017; Ziobro, 




OMIM DEE52 (Aeby 
et al., 2019)  
Colonic ICCs, colonic 
PDGFRa+ cells, colonic 
MP, colonic SP, colonic 
smooth muscle 
(O'Donnell, Nakamura, 




2019 & 2020) 
SCN2A (NAV1.2) OMIM DEE11 
(Berecki et al., 2018; 
Howell et al., 2015) 
Colonic MP, colonic 
smooth muscle (Hetz et 
al., 2014) 
Constipation, diarrhea, 
FTT, vomiting (Berecki et 
al., 2018; Howell et al., 
2015) 
SCN3A (NAV1.3) OMIM DEE62 
(Zaman et al., 2018) 
Colonic MP, colonic 
smooth muscle, 
enterochromaffin cells in 
small intestine and colon 
(Hetz et al., 2014; Strege 
et al., 2017) 
FTT (Zaman et al., 2018) 
SCN4A (NAV1.4) NDM (Gay et al., 
2008) 
Colonic smooth muscle 
(Hetz et al., 2014) 
Constipation, FTT, 
gastroesophageal reflux 
(Gay et al., 2008) 
SCN5A (NAV1.5) IBS, LQTS (Beyder 
et al., 2014; Locke, 
Ackerman, 
Zinsmeister, Thapa, 
& Farrugia, 2006; 
Saito et al., 2009; 
Strege et al., 2018) 
Colonic MP, ICCs in 
small intestine, smooth 
muscle in small intestine 
and colon (Hetz et al., 
2014; Holm et al., 2002; 
Neshatian et al., 2015; 
Ou et al., 2002; Strege, 
Holm, et al., 2003; 
Strege, Ou, et al., 2003) 
Abdominal pain, 
constipation, diarrhea 
(Beyder et al., 2014; Locke 
et al., 2006; Saito et al., 
2009; Strege et al., 2018) 
SCN8A (NAV1.6) OMIM DEE13 
(Gardella & Møller, 
2019) 




(Gardella & Møller, 2019) 
SCN9A (NAV1.7) NPS/SFN (Cannon, 
Kurklinsky, Guthrie, 
& Riegert-Johnson, 
2016; Eijkenboom et 
al., 2019; Hisama, 
Colonic MP, colonic 




(Cannon et al., 2016; 
Eijkenboom et al., 2019; 
Hisama et al., 1993) 
 5 
Dib-Hajj, & Waxman, 
1993)  
SCN10A (NAV1.8) NPS/SFN (Dabby et 
al., 2016; 
Eijkenboom et al., 
2019) 






(Dabby et al., 2016; 
Eijkenboom et al., 2019) 
SCN11A (NAV1.9) CIP, NPS/SFN 
(Eijkenboom et al., 
2019; Leipold et al., 
2013; Woods et al., 
2015) 
Colonic MP, colonic SP, 
colonic smooth muscle 
(Hetz et al., 2014; 
O'Donnell et al., 2016) 
Abdominal/perineal/rectal 
pain, constipation, 
diarrhea, enlarged colon, 
FTT, intestinal dysmotility 
(Eijkenboom et al., 2019; 
Leipold et al., 2013; 
Woods et al., 2015) 
KCNB1 (KV2.1) OMIM DEE26 
(Marini et al., 2017; 
Srivastava et al., 
2018) 
Unknown in humans; 
colonic MP in mice (Seifi 
et al., 2014) 
Constipation, FTT, 
intestinal dysmotility (Beck 
et al., 2021; Marini et al., 
2017) 
KCNQ2 (KV7.2) OMIM DEE7 (Lee, 
Chang, Liang, & Li, 
2019) 
Unknown; Kv7 channels 
localized to colonic 
sensory afferents in 
humans and colonic MP 
in mice (Jepps, 
Greenwood, Moffatt, 
Sanders, & Ohya, 2009; 
Peiris et al., 2017) 
Constipation, intestinal 
dysmotility (Beck et al., 
2021) 
 Abbreviations: CIP = congenital insensitivity to pain; DEE = developmental 
and epileptic encephalopathy; FTT = failure-to-thrive; IBS = irritable bowel 
syndrome; ICCs = interstitial cells of Cajal; LQTS = congenital long QT 
syndrome; MP = myenteric plexus; NDM = non-dystrophic myotonia; NPS = 
neuropathic pain syndromes; PDGFRa+ = platelet-derived growth factor 





1.2 The Function of Voltage-Gated Sodium Channels and their b Subunits 
 
 
Voltage-gated sodium channels (VGSCs) 
VGSCs are responsible for the initiation and propagation of action potentials (APs) in 
central and peripheral neurons, GI pacemaker cells, smooth and skeletal muscle cells, 
and cardiac myocytes – though they are also present in non-excitable cells and tissues, 
such as astrocytes, glia, cardiac fibroblasts, breast cancer cells, prostate cancer cells, 
and intestinal epithelial cells (Aronica et al., 2003; Barshack et al., 2008; Beyder & 
Farrugia, 2012; Brackenbury & Isom, 2011; Brunklaus, Ellis, Reavey, Semsarian, & 
Zuberi, 2014; Catterall, 2000; Fein, Wright, Slat, Ribera, & Isom, 2008; Maier et al., 2004; 
O'Malley & Isom, 2015; Oh, Lee, & Waxman, 1997). In neurons, VGSCs are localized at 
high density in the axon initial segment, where the AP is initiated, and – in myelinated 
neurons – in nodes of Ranvier, where APs are regenerated and thereby propagated along 
the axon during saltatory conduction (Kole et al., 2008; Komada & Soriano, 2002). VGSCs 
are thought to be important for the normal excitability of interstitial cells of Cajal (ICCs), 
which integrate enteric motor neuron input to direct GI smooth muscle relaxation and 
contraction (Strege, Ou, et al., 2003); likewise, VGSCs are also known to be concentrated 
at neuromuscular junctions, where they conduct sodium ions and thus initiate APs in 
skeletal muscle fibers (Simkin & Bendahhou, 2011). In cardiomyocytes, VGSCs are 
primarily clustered at the intercalated disks and t-tubules, where they are vital for normal 
conduction velocity and excitation-contraction coupling (Dhar Malhotra et al., 2001; Haufe 
et al., 2005; Kaufmann et al., 2013; Maier et al., 2004). 
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Each VGSC is a heterotrimeric protein complex composed of one pore-forming a subunit 
and two distinct b subunits: either a b1 or b3, which non-covalently associate with the a 
subunit, and a  b2 or b4, which covalently associate with the a subunit via disulfide bonds 
(Catterall, 2000; Isom et al., 1992; Morgan et al., 2000; O'Malley & Isom, 2015; Yu et al., 
2003). There are nine identified VGSC a subunits, Nav1.1-Nav1.9, which can be 
categorized by their relative sensitivity to tetrodotoxin (TTX) (Table 1.2) (Catterall, Goldin, 
& Waxman, 2005; O'Malley & Isom, 2015). TTX-sensitive (TTX-S) VGSC a subunits can 
be blocked by nanomolar concentrations of TTX, while TTX-resistant (TTX-R) VGSC a 
subunits require micromolar concentrations of TTX to impair function (Catterall et al., 
2005; O'Malley & Isom, 2015). VGSC b subunits regulate channel activity and cell-surface 
expression in addition to functioning as cell adhesion molecules (CAMs) and 
transcriptional modulators (Aeby et al., 2019; Bouza et al., 2021; Calhoun & Isom, 2014; 
Isom, 2001, 2002; Isom & Catterall, 1996). There are five known VGSC b subunits 
encoded by four genes (Table 1.2) (O'Malley & Isom, 2015). The genes encoding these 
b subunits are involved in myriad physiological processes throughout the body, and b 
subunit gene variants have been implicated in pathologies such as ataxia, autism, cancer, 
cardiac arrhythmia, epilepsy, neurodegeneration, neuropathic pain, and sudden 
unexpected death in epilepsy (SUDEP) (Aeby et al., 2019; Calhoun & Isom, 2014; 


















b  SUBUNIT 
PROTEIN(S) 
SCN1A Nav1.1 TTX-S SCN1B b1, b1B 
SCN2A Nav1.2 TTX-S SCN2B b2 
SCN3A Nav1.3 TTX-S SCN3B b3 
SCN4A  Nav1.4 TTX-S SCN4B b4 
SCN5A Nav1.5 TTX-R   
SCN8A  Nav1.6 TTX-S   
SCN9A Nav1.7 TTX-S   
SCN10A  Nav1.8 TTX-R   
SCN11A  Nav1.9 TTX-R   
 
 
VGSC b1/b1B subunits 
 
This thesis focuses on the physiological roles of VGSC b1/b1B subunits. SCN1B encodes 
the VGSC b1 subunit and its soluble splice variant, b1B, which play roles in cell signaling 
and modulate both sodium and potassium currents (Aeby et al., 2019; Brackenbury & 
Isom, 2011; Davis, Chen, & Isom, 2004; Hull et al., 2020; Lopez-Santiago, Brackenbury, 
Chen, & Isom, 2011; Lopez-Santiago et al., 2007; O'Malley & Isom, 2015; Patino et al., 
2009; Patino & Isom, 2010; Yuan et al., 2019). b1 is a transmembrane protein that 
associates with VGSC a subunits, potassium channel a subunits, CAMs, extracellular 
matrix proteins, and cytoskeletal proteins (Brackenbury et al., 2010; Brackenbury & Isom, 
2011; Calhoun & Isom, 2014; Marionneau et al., 2012; McEwen & Isom, 2004). b1B is a 
developmentally regulated, secreted SCN1B isoform that modulates Nav1.5-mediated 
sodium current (INa) – but not INa generated by TTX-sensitive VGSCs – and functions as 
a soluble ligand for cell adhesion (Patino et al., 2011). b1 and b1B exhibit inverse 
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expression patterns in the developing rodent brain; b1B is primarily expressed during 
embryonic development and early life, while b1 expression becomes detectable during 
postnatal development and peaks during adulthood (Isom et al., 1992; Kazen-Gillespie et 
al., 2000; Patino et al., 2011). Conversely, b1B expression remains high in the rodent 
cardiac system into adulthood (Edokobi & Isom, 2018; Kazen-Gillespie et al., 2000). 
 
Importantly, variants in SCN1B are linked to disease. A subset of DEE patients has 
homozygous recessive loss-of-function (LOF) variants in SCN1B, and physicians report 
that these SCN1B-linked DEE (DEE52) patients exhibit intractable seizures, 
developmental delay, ataxia, and increased risk for SUDEP (Aeby et al., 2019; Ogiwara 
et al., 2012; Patino et al., 2009; Personal_Communication, 2019 & 2020; Ramadan et al., 
2017). DEE52 patients are also reported to exhibit GI symptoms, including constipation 
(Personal_Communication, 2019 & 2020). Additionally, a recent clinical study showed 
reduced SCN1B mRNA expression in both ganglionic and aganglionic portions of colon 
in HSCR patients (O'Donnell et al., 2019).  
 
VGSC b subunits were traditionally thought to be accessory proteins that functioned to 
modulate the gating and kinetics of VGSCs. Foundational experiments in Xenopus 
oocytes showed that co-expression of b1 with Nav1.2 accelerates the channel’s 
inactivation, shifts the voltage dependence of inactivation to more negative membrane 
potentials, and increases the size of the peak sodium current (Isom et al., 1992). When 
expressed in immortalized mammalian cell lines, b1 was similarly observed to increase 
peak sodium current density and induce a negative shift in the voltage dependence of 
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inactivation yet had no effect on the rate of inactivation in these systems (Aeby et al., 
2019; McEwen, Meadows, Chen, Thyagarajan, & Isom, 2004; Meadows et al., 2002; 
Patino et al., 2009).  Additionally, experiments performed in mammalian cell lines show 
that b1/b1B subunits influence a subunit surface expression; however, the observed 
impact of b1/b1B subunits differed based on the cell line used in a given study (Calhoun 
& Isom, 2014; Kazarinova-Noyes et al., 2001; Kazen-Gillespie et al., 2000; McEwen et 
al., 2004).  
 
Studies performed in heterologous or other in vitro systems established key projections 
for the context-dependent, physiological roles of b1 subunits in vivo. Scn1b-null mice, 
which lack b1 and b1B expression, exhibit a phenotype which mirrors the symptoms of 
DEE52 patients – including spontaneous and generalized seizures, failure-to-thrive, 
ataxia, and premature death around post-natal day (P) 19 (Chen et al., 2004; Yuan et al., 
2019). Mouse studies have also reinforced the canonical roles of VGSC b1 subunits: 
modulating the cell-surface expression and activity of the VGSC a subunits. Recent work 
in the Isom lab suggests that the cleaved intracellular domain of b1 subunits can 
translocate to the nucleus and regulate gene transcription of VGSCs as well as other 
voltage-gated ion channels (VGICs) (Bouza et al., 2021). The Scn1b-null hippocampal 
CA3 region has decreased Nav1.1 expression and increased Nav1.3 expression 
compared to aged-matched wild-type (WT) mice (Chen et al., 2004). Scn1b-null cardiac 
myocytes also exhibit increased Nav1.3 levels in addition to increased Nav1.5 expression, 
and dorsal root ganglion (DRG) neurons exhibit decreased cell-surface Nav1.9 expression 
(Brackenbury et al., 2010; Lin et al., 2015; Lopez-Santiago et al., 2011; Lopez-Santiago 
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et al., 2007). These studies show that VGSC b1 subunits impact VGSC a subunit 
expression levels in the CNS, peripheral nervous system (PNS), which consists of the 
nerves and ganglia located outside of the brain and spinal cord, and cardiac system in a 
cell-type-specific manner. 
 
Scn1b deletion results in cell-type-specific effects on excitability in the CNS, PNS, and 
cardiac systems. Previous work suggests Scn1b-null cerebellar neurons are 
hypoexcitable, while Scn1b-null cortical pyramidal neurons exhibit a biphasic response in 
which they are hyperexcitable at lower injected currents and hyperexcitable at higher 
injected currents (Hull et al., 2020; Reid et al., 2014). In addition to VGSCs, b1 subunits 
influence activity of voltage-gated potassium channels (VGKCs); co-immunoprecipitation 
experiments suggest that b1 and Kv4.2 interact in mouse brain, and knockdown of b1 in 
cultured cortical neurons reduced potassium current, likely due to decreased cell-surface 
expression of VGKCs (Kearney, 2013; Marionneau et al., 2012). Furthermore, nociceptive 
Scn1b-null DRG neurons are hyperexcitable, due to modulations in both sodium and 
potassium currents (INa and IK, respectively) (Lopez-Santiago et al., 2011). These data 
show that Scn1b plays an important role in maintaining normal excitability in neurons and 
other excitable cells throughout the body.  
 
As well as playing an integral role in channel modulation, b1 subunits are members of the 
immunoglobulin superfamily of cell adhesion molecules (CAMs), which regulate cell 
adhesion, proliferation, and migration (Brackenbury & Isom, 2011; Calhoun & Isom, 
2014). Furthermore, b1 subunits have been shown to modulate axon outgrowth and 
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pathfinding (Brackenbury et al., 2010; Brackenbury et al., 2008; Calhoun & Isom, 2014; 
Davis et al., 2004). These additional functions of b1 subunits suggest their importance in 
normal nervous system development. Scn1b-null mice have significantly fewer nodes of 
Ranvier in optic nerve, aberrations in axo-glial junctions in CNS and PNS axons, and 
reduced myelination of sciatic nerve and spinal cord (Chen et al., 2004). Previous studies 
show that both the extracellular domain of b1 and its soluble splice variant, b1B, promote 
neurite outgrowth in cerebellar granule neurons via CAM-mediated signaling (Davis et al., 
2004; McEwen & Isom, 2004; Patino et al., 2011). These small neurite extensions 
protruding from immature neurons establish polarity, develop into axons and dendrites, 
and begin to form the connections that eventually define a neural circuit. In the CNS, it 
has been shown that b1/b1B subunits mediate axon fasciculation, the process by which 
growing axons adhere to one another to limit the dispersion of axonal tracks and generate 
more precise connections between regions (Brackenbury, Yuan, O'Malley, Parent, & 
Isom, 2013). Scn1b-C121W mice, a mouse model based on a human SCN1B variant, 
exhibit reduced dendritic arborization in the pyramidal neurons of the somatosensory 
cortex (Reid et al., 2014). Scn1b-null mice, which lack b1/b1B-mediated neuronal 
outgrowth, exhibit disrupted axonal pathfinding and fasciculation in the cerebellum as well 
as in the corticospinal tract (Brackenbury et al., 2008). These data show that VGSC b1 
subunits are vital for the formation of proper neuronal networks.  
 
In conclusion, the vital roles that VGSC b1 subunits play in mammalian neuronal 
excitability and development have been extensively studied and documented in the brain 
and spinal cord; however, CNS neurons are not the only neurons in the body known to 
express VGSCs. The largest population of neurons located outside the CNS is the enteric 
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nervous system situated in the GI tract, and the potential function(s) of b1 subunits in 
these neurons has not yet been established.  
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1.3 The Gastrointestinal Tract and Enteric Nervous System Function 
 
The digestive system and gastrointestinal tract 
 
The overall function of the digestive system is to is to chemically and mechanically break 
down ingested material, absorb the resulting nutrient molecules, and then excrete the 
remaining fecal material (Ogobuiro, Gonzales, & Tuma, 2021). The key digestive organs 
– in order of food processing – are the oral cavity, pharynx, esophagus, stomach, small 
intestine (also referred to as the small bowel), and large intestine (also referred to as the 
large bowel or colon). This section will focus primarily on the roles of the small and large 
intestines. 
 
The vast majority (90%) of food molecule and nutrient absorption occurs in the small 
intestine (Ogobuiro et al., 2021). The small intestine is segmented into three portions: the 
most “proximal” portion - duodenum, which receives contents from the stomach, jejunum, 
and the most “distal” portion - ileum, which releases contents to the large intestine (Fish 
& Burns, 2021; Ogobuiro et al., 2021). The small intestine produces and secretes a large 
amount of hormones and enzymes in response to the specific components of the 
materials passing through, enabling it to digest and absorb carbohydrates, proteins, lipids, 
vitamins, and minerals (Fish & Burns, 2021). The epithelial layer of the small intestine, 
which borders the intestinal lumen through which the digested materials flow, is highly 
convoluted; these villi and microvilli increase the surface area available for absorption of 
nutrients (Fish & Burns, 2021; Ogobuiro et al., 2021). After passing through the small 
intestine, digested material moves to the colon. The colon is primarily responsible for 
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absorbing water and electrolytes and then finally excreting the fecal material from the 
body through the rectum (Debongnie & Phillips, 1978; Ogobuiro et al., 2021; Phillips & 
Giller, 1973). In the small and large bowels, coordinated contractions and relaxations 
move material to the next location while mixing the ingested food with digestive enzymes 
and intestinal secretions, thus enabling nutrient breakdown into absorbable materials as 
well as exposing these materials to the lumen for subsequent absorption; all of these 
activities are primarily controlled by localized neuronal networks known as the enteric 
nervous system (ENS) (Hansen, 2003; Huizinga et al., 2011). 
 
The organization and function of the enteric nervous system 
The peripheral nervous system (PNS) composes the nerves and ganglia that are located 
outside the brain and spinal cord; a component of the PNS is the autonomic nervous 
system (ANS), which regulates involuntary physiological functions (Waxenbaum, Reddy, 
& Varacallo, 2021). The largest branch of the ANS is the ENS, an extensive network of 
over 100 million neurons embedded in the walls of the intestinal tract (M. Rao & Gershon, 
2016; Waxenbaum et al., 2021). The ENS is capable of regulating GI functions 
independently of input from brain or spinal cord; this ability is particularly apparent in the 
small and large intestines, which retain normal motility patterns in the complete absence 
of CNS innervation (M. Rao & Gershon, 2016; Waxenbaum et al., 2021).  
 
The ENS is composed of two neuronal plexuses: the submucosal plexus and the 
myenteric plexus. The submucosal plexus is located only in the small and large bowel, 
while the myenteric plexus extends the entire length of the GI tract (Furness, Callaghan, 
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Rivera, & Cho, 2014). Previous studies have shown that the myenteric plexus develops 
before the submucosal plexus, though both are present well before birth in mammals 
(Pham, Gershon, & Rothman, 1991; M. Rao & Gershon, 2018). A recent study in mice 
showed that neurons in the myenteric plexus, though not the submucosal plexus, 
organize into “stripes” perpendicular to the longitudinal axis of the intestine – in the same 
orientation as circular muscle rings (Hamnett et al., 2021). Another study showed that 
specific planar cell polarity genes may be linked to enteric axon guidance, and that small 
changes in ENS organization can lead to large alterations in GI motility (Sasselli et al., 
2013).  However, relatively little is known about how the nascent neurons in both plexuses 
then establish the functional connections that enable them to sense the local environment 
as well as signal to other neurons and effector cells within the GI tract. 
 
Neurons in the submucosal plexus, located directly beneath the mucosal layer of the 
intestinal wall, monitor luminal stimuli as well as regulate secretion and absorption; 
neurons in the myenteric plexus, located deeper within the two muscular layers of the 
intestinal wall, primarily control bowel motility patterns by coordinating intestinal 
contractions and relaxations (Avetisyan, Schill, & Heuckeroth, 2015; Foong, Tough, Cox, 
& Bornstein, 2014; Furness et al., 2014; Hansen, 2003). Within these two plexuses, there 
are approximately 20 distinct types of enteric neurons, which can be differentiated by 
function, morphology, connections, neurotransmitters, and electrophysiological 
signatures (Avetisyan et al., 2015; Furness, 2000). The myriad enteric neurons can be 
broadly divided into three main classes: intrinsic sensory neurons (commonly referred to 
as intrinsic primary afferent neurons [IPANs]), which detect and coordinate responses to 
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physical distension and chemical contents of the lumen; motor neurons, which can 
innervate the circular and longitudinal smooth muscle layers of the intestine to control 
intestinal motility, innervate the mucosa to induce secretions into the intestinal lumen, or 
innervate vessels to influence mucosal blood flow; and interneurons, which help to enable 
signaling between all classes of enteric neurons (Figure 1.1) (Avetisyan et al., 2015; Fung 
& Vanden Berghe, 2020; Furness, 2000; Furness et al., 2014; M. Rao & Gershon, 2016). 
Interneurons and motor neurons exhibit unipolar morphology and are also categorized as 
“S” or “Type I” neurons; while the sensory IPANs are multipolar and are often referred to 
as “AH” or “Type II” neurons (G. D. Hirst, Holman, & Spence, 1974).  
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Figure 1.1: Overview of major enteric neuron subtypes. Intrinsic sensory neurons 
(IPANS), with cell bodies in both the submucosal plexus (SMP) and myenteric plexus 
(MP) innervate the mucosa surrounding the intestinal lumen. In the MP, ascending 
interneurons, which innervate excitatory motor neurons, project orally while descending 
interneurons, which innervate inhibitory motor neurons, project anally. Excitatory and 
inhibitory motor neurons project to both the circular (CM) and longitudinal (LM) smooth 
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muscle layers of the GI tract to produce coordinated contractions and relaxations. Caption 
modified from and figure reproduced from (Fung & Vanden Berghe, 2020), an open 
access article under the Creative Commons CC BY license. 
 
Enteric neurons are not the only major excitable cell type localized in the GI tract. Chemo- 
and mechano-sensitive enterochromaffin cells, located in the intestinal epithelium, 
regulate fluid secretion (Alcaino et al., 2018; Linan-Rico et al., 2016; Strege et al., 2017). 
The muscular tissues of small and large bowel are made up of smooth muscle cells 
(SMCs) (Sanders, Koh, Ro, & Ward, 2012). SMCs are intrinsically excitable; however, in 
order to produce the stereotyped patterns of intestinal activity, SMCs must be modulated 
by enteric neurons as well as two types of interstitial cells: the interstitial cells of Cajal 
(ICCs), which are pacemakers for cyclical slow waves, and platelet-derived growth factor 
positive-a-receptor (PDGFRa+) cells (Furness, 2000; Hansen, 2003; Huizinga et al., 
1995; Sanders et al., 2012; Schneider, Wright, & Heuckeroth, 2019; Thomsen et al., 1998; 
Y. F. Zhu et al., 2014). These interstitial cells, which are also innervated by enteric 
neurons, electrically couple to circular and longitudinal SMCs via gap junctions to 
coordinate excitatory and inhibitory neural input with SMC contraction and relaxation 
(Cousins, Edwards, Hickey, Hill, & Hirst, 2003; Furness, 2000; Hansen, 2003; Horiguchi 
& Komuro, 2000; Huizinga et al., 1995; Sanders et al., 2012; Schneider et al., 2019).  
 
Nearly all CNS neurotransmitters have also been found in ENS (Furness, 2000; Furness 
et al., 2014; M. Rao & Gershon, 2016). Secretomotor and vasomotor neurons control and 
coordinate intestinal secretions and blood flow, respectively. In response to mechanical 
and chemical luminal stimuli, secretomotor neurons primarily use vasoactive intestinal 
peptide (VIP) and substance P (SP) to signal to epithelial receptors and modulate 
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secretions and absorptions (Furness, 2007; Hansen, 2003; Hansen & Skadhauge, 1997; 
Reed & Vanner, 2001, 2003). Cholinergic vasomotor neurons ensure that mucosal blood 
flow is sufficient to fuel intestinal activities and allow for normal fluid exchange across the 
intestinal epithelium as water accompanies the influx of nutrient molecules from the lumen 
and efflux of electrolytes to the lumen (Furness, 2007; Hansen, 2003). Enterochromaffin 
cells synthesize 95% of the body’s serotonin (5-HT), and they respond to mucosal 
stimulation by releasing 5-HT to IPANs (Alcaino et al., 2018; Bertrand, 2004; Linan-Rico 
et al., 2016; Strege et al., 2017). In turn, IPANs – which are immunoreactive for choline 
acetyltransferase (ChAT), an enzyme that synthesizes acetylcholine (ACh), as well as 
calbindin – stimulate interneurons (Furness, Costa, & Keast, 1984; Niel, 1991). Orally 
projecting, ascending interneurons stimulate excitatory motor neurons, while anally 
projecting, descending interneurons act on inhibitory motor neurons; both types of 
interneurons largely signal using ACh (Brookes, 2001; Furness, 2000; Furness & Costa, 
1982; Li & Furness, 1998; Qu et al., 2008). Excitatory motor neurons are thought to 
release ACh, adenosine triphosphate (ATP), and tachykinins to interstitial cells and 
SMCs, while the major co-transmitters for the inhibitory motor neurons are nitric oxide 
(NO) and ATP (Furness, 2000; Greig & Cowles, 2017; Hansen, 2003; Qu et al., 2008; 
Schneider et al., 2019). ACh and tachykinins act on muscarinic ACh receptors (mAChRs) 
and neurokinin receptors on GI SMCs, respectively, to induce smooth muscle contraction 
(Cousins, Edwards, Hirst, & Wendt, 1993; Maggi et al., 1997). NO diffuses to local SMCs 
and induces smooth muscle relaxation through cyclic guanosine monophosphate 
(cGMP)-mediated signaling (Sanders & Ward, 1992). The neurotransmitter ATP is able 
produce either excitatory or inhibitory responses depending on the receptor present on 
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the postsynaptic cell; ligand-gated P2X receptors – along with nicotinic ACh receptors 
(nAChRs) – are localized to excitatory motor neurons, while G-protein-coupled P2Y 
receptors are found on inhibitory motor neurons (Galligan, LePard, Schneider, & Zhou, 
2000; Giaroni et al., 2002; Ren & Bertrand, 2008). 
 
Due to differences in neurotransmitter receptors and electrophysiological responses 
observed in ICCs versus PDGFRa+ cells, it is thought that the two populations of 
interstitial cells are activated by different components of the enteric motor neuron 
signaling pathway. ICCs, which express mAChRs and neurokinin receptors, are thought 
to be the major recipients of cholinergic and signaling from excitatory motor neurons and 
the nitrergic signaling component from inhibitory motor neurons (Alberti et al., 2007; Iino 
& Horiguchi, 2006; Kito & Suzuki, 2003; Klein et al., 2013; Suzuki, Ward, Bayguinov, 
Edwards, & Hirst, 2003; X. Y. Wang, Paterson, & Huizinga, 2003). PDGFRa+ cells can 
be differentiated from ICCs by their robust expression of purinergic signaling proteins, 
such as the P2Y1 receptor, suggesting that these interstitial cells are the primary recipient 
of the ATP signaling component from inhibitory motor neurons (Kurahashi, Mutafova-
Yambolieva, Koh, & Sanders, 2014; Peri, Sanders, & Mutafova-Yambolieva, 2013). 
 
The excitatory and inhibitory motor neurons are the main drivers of intestinal contractions 
and relaxations, respectively. My thesis work aimed to understand the physiological 
causes of constipation and dysmotility in SCN1B-linked DEE as well as determine the 
role of SCN1B subunits in maintaining normal colonic motility; therefore, I will focus 
primarily on the activity of these excitatory and inhibitory motor neurons and how 
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temporally and spatially synchronized signaling between these two populations – both 
located in the myenteric plexus – produces the observed neurogenic motility pattens 
observed in the large intestine. My work will also touch on the IPANs and interstitial cells 
that mediate these motility responses. 
 
Development and patterns of colonic motility  
There are multiple distinct forms of motility that have been observed in the large intestine 
of humans and other mammals. These stereotyped, controlled smooth muscle 
movements are established by 1) “myogenic” activity that is intrinsic to GI smooth muscle 
and pacemaker cells and 2) “neurogenic” activity that is controlled by the inhibitory and 
excitatory motor neurons of the myenteric plexus and even influenced by external 
autonomic innervation (Spencer, Dinning, Brookes, & Costa, 2016).  
 
It has been well-established that inhibitory signaling typically arises earlier in development 
than excitatory signaling in the mammalian ENS. Studies performed in neonatal guinea 
pigs suggest inhibitory neuromuscular transmission to longitudinal muscle in small 
intestine is stronger than in adult guinea pigs (Bian, Burda, Carrasquillo, & Galligan, 2009; 
Patel et al., 2010). While evidence of inhibitory ENS signaling to circular smooth muscle 
is already present at birth in mice, excitatory neuromuscular transmission to circular 
SMCs is not thought to develop until sometime between P6 and P10 – which coincides 
with the proportions of myenteric cholinergic neurons in murine small intestine finally 
reaching “adult” levels (Hao, Bornstein, & Young, 2013; Roberts, Murphy, Young, & 
Bornstein, 2007). Similarly, the proportion of nitrergic colonic myenteric neurons stabilizes 
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by P5 in rats, while the proportion of cholinergic enteric neurons continues to increase 
through P36 (de Vries, Soret, Suply, Heloury, & Neunlist, 2010). Though the precise 
development of enteric neuronal expression and activity is difficult to establish in humans, 
one study used dissected small intestine tissue from children (< 2 years old) and adults 
to compare ex vivo motility (Wittmeyer, Merrot, & Mazet, 2010). Though both adolescent 
and adult tissue exhibited spontaneous contractions, researchers found that NO 
neurotransmission exhibited a stronger, tonic inhibitory action in adolescent intestine 
(Wittmeyer et al., 2010). In summary, typical neurogenic patterns of intestinal motility are 
age-dependent, largely due to the delayed emergence of cholinergic enteric neurons and 
excitatory neuromuscular signaling.  
 
Slow waves: Slow waves are spontaneous, rhythmic, undulating changes in the resting 
membrane potential of GI smooth muscle (M. K. K. Cheng H.M., Seluakumaran K. , 2020). 
These electrophysiological events are actively generated and propagated by the ICC 
network and then passively conducted to the surrounding SMCs via gap junctions (M. K. 
K. Cheng H.M., Seluakumaran K. , 2020; Furness, 2007; Sanders, 2019). Though slow 
waves in isolation are insufficient to induce smooth muscle contraction, input from the 
ENS and other external influences can result in the membrane potential reaching the 
“slow wave threshold” – at which point the smooth muscle membrane potential is 
sufficiently depolarized to initiate APs, cause an influx of calcium ions through open L-
type voltage-gated calcium channels, and initiate smooth muscle contraction by 
excitation-contraction coupling (M. K. K. Cheng H.M., Seluakumaran K. , 2020; Sanders, 
2019; Thorneloe & Nelson, 2005).  
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Colonic migrating motor complexes (CMMCs): CMMCs are neurally mediated; however, 
these cyclical motor patterns are thought to be less content-dependent and are therefore 
more prevalent in the fasted state (M. K. K. Cheng H.M., Seluakumaran K., 2020; Spencer 
et al., 2016). Unlike peristaltic contractions, CMMCs are capable of migrating both orally 
and arborally (Sanders, 2019; Sarna, Condon, & Cowles, 1984). The main purpose of this 
motility pattern is likely to clear the intestinal lumen of food remnants, residual secretions, 
and cellular debris in between meals (Beckett, Young, Bornstein, & Jadcherla, 2017). 
While the exact neurogenic signaling mechanisms underlying CMMCs are unclear, it has 
been proposed that these motility patterns are generated by either a reduction in tonic 
signaling from inhibitory motor neurons or are produced exclusively via synergistic 
signaling from excitatory motor neurons and ICCs (Brierley, Nichols, Grasby, & 
Waterman, 2001; Dickson, Heredia, McCann, Hennig, & Smith, 2010; Roberts et al., 
2007; Spencer, 2001).  
 
Peristalsis: The peristaltic reflex is a neurally mediated contractile response to luminal 
content (Figure 1.2). Fecal material or a “bolus” in the large intestine can mechanically 
and chemically activate enterochromaffin cells in the lumen epithelium, causing these 
cells to release 5-HT to IPANS (Alcaino et al., 2018; Bertrand, 2004; Linan-Rico et al., 
2016; Strege et al., 2017). There is also evidence that certain excitatory and inhibitory 
interneuron populations are mechanosensitive to specific types of stretch and that their 
signaling complements that of the IPANs during the peristatic reflex (Smith, Spencer, 
Hennig, & Dickson, 2007). This signaling pathway(s) ultimately results in both excitatory 
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and inhibitory neuronal signaling to SMCs in both circular and longitudinal GI muscle 
layers, which moves the material in an aboral direction via a polarized reflex response 
(Spencer et al., 2016). In the segment directly distal to the bolus, smooth muscle 
relaxation produces an expanded GI “pocket” that receives the moving materials 
(Spencer, Hennig, & Smith, 2003; Wood, 2004). In the intestinal segment directly proximal 
to the luminal content, smooth muscle contractions propel the contents to the newly 
formed pocket (Spencer et al., 2003; Wood, 2004). Once the bolus is pushed to its new, 
more distal location in the intestinal lumen, it activates the same reflex response again; 
this pattern continues until the material exits the intestinal tract (Spencer et al., 2016).  
 
 
Figure 1.2: An overview of the peristaltic reflex. Intrinsic sensory afferents, detecting 
a stimulus in the intestinal lumen, signal to ascending and descending interneurons. 
Excited by the ascending interneurons, excitatory motor neurons signal to circular and 
longitudinal muscle to produce an oral contraction; in tandem, inhibitory motor neurons – 
innervated by descending interneurons, produce an anal relaxation. Caption modified 
from and figure reproduced from (Fung & Vanden Berghe, 2020), an open access article 
under the Creative Commons CC BY license.  
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The patterns of colonic motility – and thus the proper functioning of the enteric neurons, 
interstitial pacemaker cells, and effector SMCs that initiate and control them – are vital for 
normal digestion and excretion. In turn, the excitability and signaling capacity of these 
ENS cell populations is largely dependent on VGICs.     
 
Overview of voltage-gated ion channels in ENS development and intestinal motility 
VGSCs: Electrophysiological recordings from human intestinal pacemaker cells (Strege, 
Ou, et al., 2003) and smooth muscle (Holm et al., 2002) have shown that TTX-R VGSC 
activity is likely involved in regulating intestinal electrical slow waves and subsequently 
smooth muscle contractions. Patient variants in SCN5A have been shown to alter INa 
density as well as voltage-dependence and VGSC mechanosensitivity in experiments 
performed in heterologous cells (Saito et al., 2009; Strege et al., 2018). Furthermore, 
ranolazine, a drug that selectively blocks Nav1.5-mediated INa and causes constipation in 
patients, was shown to reduce peak INa and VGSC mechanosensitivity in isolated human 
colonic smooth muscle cells as well as decrease both basal and stimulation-induced 
contractility in human colonic muscle segments (Neshatian et al., 2015). An analysis of 
colon tissue samples taken from patients with Hirschsprung’s disease, a condition 
characterized by problems passing stool, revealed decreased Nav1.9 protein expression 
relative to control human colon samples (O'Donnell et al., 2016).  
 
Work in animal models suggests that Nav1.5 and Nav1.9 play important roles in controlling 
the firing patterns of mammalian enteric neurons, with both VGSCs being expressed by 
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enteric motor neurons and Nav1.9 being localized primarily to IPANS (Osorio, Korogod, 
& Delmas, 2014). More specifically, a study performed in mice lacking Nav1.9 showed 
altered colonic contractility patterns, suggesting that intestinal VGSC activity is crucial for 
regulating gut motility in mammals (Copel, Clerc, Osorio, Delmas, & Mazet, 2013). There 
is also substantial evidence for TTX-S VGSC a subunit involvement in in both Type I and 
Type II enteric neuron action potential generation as well as patterns of colonic motility, 
due to the striking observed effect of TTX on these activities (Fida, Lyster, Bywater, & 
Taylor, 1997; G. D. Hirst et al., 1974; Nakagawa, Misawa, Nakajima, & Takaki, 2005). 
The exact identities of the TTX-S VGSC a subunits that contribute to enteric neuron action 
potentials have not been verified, but mRNA expression of Scn2a, Scn3a, Scn8a, and 
Scn9a has been observed in mammalian small and large intestine (Bartoo, Sprunger, & 
Schneider, 2005; Sage et al., 2007). Additionally, epithelial enterochromaffin cells are 
also known to express Nav1.3, which is thought to be important for their excitability and 
5-HT release (Strege et al., 2017).  
 
Voltage-gated calcium channels (VGCCs): In addition to the L-type Cav channels (Cav1) 
which enable smooth muscle contraction, VGCCs are also localized to interstitial cells 
and enteric neurons. T-type VGCCs (Cav3) are expressed by murine ICCs, where they 
are important for synchronizing pacemaker activity and propagating slow waves (Beyder 
& Farrugia, 2012; Y. C. Kim, Koh, & Sanders, 2002; Zheng, Park, Koh, & Sanders, 2014). 
Cav2.2 (N-type) is the predominant VGCC expressed by mammalian enteric neurons and 
are thought to largely control ACh release in myenteric plexus; Cav2.3 (R-type) also plays 
a role in ENS signaling – more specifically, in controlling release of particular 
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neurotransmitters from inhibitory motor neurons (Bian, Zhou, & Galligan, 2004; Rugiero 
et al., 2002; Shuttleworth & Smith, 1999; Smith, Kang, & Vanden Berghe, 2003; Vogalis, 
Harvey, Lohman, & Furness, 2002; Wessler, Dooley, Werhand, & Schlemmer, 1990). It 
is thought that inhibitory motor neurons co-release ATP and NO to induce smooth muscle 
relaxations (Mane et al., 2014). Cav2.2 is postulated to mediate the release of ATP from 
inhibitory motor neurons, while Cav2.3 drives the release of NO (Bridgewater, Cunnane, 
& Brading, 1995; E. S. Rodriguez-Tapia, Naidoo, DeVries, Perez-Medina, & Galligan, 
2017).  
 
Voltage-gated potassium channels (VGKCs): The enteric nervous system (ENS) 
develops from enteric neural crest-derived cells (ENCCs) that migrate to the foregut 
during mammalian embryonic development (Hao et al., 2012; C. S. Hirst et al., 2015). 
Researchers have noted robust Kv3.4 expression on neurites close to the murine ENCC 
migratory wavefront, but there is no solid evidence that these channels influence ENCC 
migration or generation of enteric neurites (C. S. Hirst et al., 2015). Kv1 and Kv4 channel 
activity and/or expression have been found in ICCs and GI SMCs (Amberg, Koh, 
Imaizumi, Ohya, & Sanders, 2003; Beyder & Farrugia, 2016; Hart et al., 1993; Hatton et 
al., 2001; Y. C. Kim et al., 2002; Overturf et al., 1994; Parsons & Huizinga, 2010). 
Additionally, the Kv7 channel family is thought to play a role in mediating noxious chemical 





The ENS is a vast, complex physiological system that relies on a plethora of cell types, 
local connections, and signaling pathways to develop and operate properly. Many of 
these foundational mechanisms are similar to those that ensure appropriate functioning 
of the CNS, and there are many examples of comorbid CNS and ENS dysfunction in the 
patient population. VGSC a and b1 subunits influence cell excitability, neuronal 
development and patterning, and the expression patterns of other ion channel genes. 
Variants in SCN1B alter neuronal activity and cause various forms of developmental 
delay; recently, SCN1B was also linked to ENS function in the patient population. There 
are many anecdotal reports and clinical case studies suggesting that VGSC-associated 
gene variants – including SCN1B – are linked to GI dysfunction, including dysmotility and 
constipation. However, the precise role of VGSC b1 subunits in GI motility remains 
unknown. The research presented in Chapter 2 of this thesis provides a strong rationale 
for the direct involvement of ENS-localized VGICs in the colonic dysmotility experienced 
by many DEE patients. Subsequently, in Chapter 3 I assess the specific effects of Scn1b 
deletion in the development, organization, and function of the colonic myenteric plexus in 




Chapter 2 : Gastrointestinal Symptomology in Developmental and 
Epileptic Encephalopathy Patients 
 
A modified version of this chapter has been published:  
Beck V.C., Isom L.L., Berg A.T. Gastrointestinal symptoms and channelopathy-
associated epilepsy. J Pediatr. 2021 Jun 25:S0022-3476(21)00616-8. 





The objective of this work was to determine the prevalence of and identify factors 
associated with gastrointestinal (GI) symptoms among patients with channelopathy-
associated developmental and epileptic encephalopathy (DEE). Parents of 168 patients 
with DEEs linked to SCN1A (N=59), KCNB1 (N=31), or KCNQ2 (N=78) completed online 
CLIRINX© surveys about their children’s GI symptoms. Analysis examined prevalence, 
frequency, and severity of GI symptoms, as well as DEE type, functional mobility, feeding 
difficulties, ketogenic diet, anti-seizure medication, autism spectrum disorder (ASD), and 
seizures. Statistical analyses included chi-square tests, Wilcoxon rank-sum analyses, 
and multiple logistic regression.  
 
GI symptoms were reported in 92/168 (55%) patients among whom 63/86 (73%) reported 
daily or weekly symptoms, 29/92 (32%) had frequent or serious discomfort, and 13/91 
(14%) had frequent or serious appetite disturbances as a result. The prevalence of GI 
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symptoms varied across DEE cohorts with 44% of SCN1A-DEE patients, 35% of KCNB1-
DEE patients, and 71% of KCNQ2-DEE patients reporting GI symptoms in the previous 
month. After adjustment for DEE type, current use of ketogenic diet (6% reported), and 
gastrostomy tube (13% reported) were both associated with GI symptoms in a 
statistically, but not clinically significant manner (P < 0.05). Patient age, functional 
mobility, feeding difficulties, ASD, and seizures were not clearly associated with GI 
symptoms. Overall, no individual anti-seizure medication was significantly associated with 
GI symptoms across all DEE cohorts. 
 
GI symptoms are common and frequently severe in DEE patients. Understanding GI 
symptoms in DEEs is essential for guiding future work to investigate how variants in 
voltage-gated ion channel genes may directly contribute to GI pathology via alterations in 








Patients with developmental and epileptic encephalopathies (DEEs) often exhibit a wide 
range of impairments, which can complicate treatment and reduce quality of life (A. T. 
Berg, Tarquinio, & Koh, 2017). One often distressing concern that is repeatedly found in 
clinical reports of patients with DEE, including those with variants in genes encoding 
voltage-gated ion channels, is gastrointestinal (GI) dysfunction, particularly constipation 
and dysmotility (Berecki et al., 2018; A. T. Berg et al., 2017; Cannon et al., 2016; Dabby 
et al., 2016; Fertleman et al., 2006; Gardella & Møller, 2019; Gay et al., 2008; Hisama et 
al., 1993; Howell et al., 2015; Leipold et al., 2013; Srivastava et al., 2018; Villas et al., 
2017; Wirrell et al., 2017). These anecdotal reports, however, have not been 
systematically explored or characterized.  
 
Multiple factors may be linked to the development of GI symptoms in the DEE patient 
population. Physical inactivity contributes to constipation in the general population 
(Center, 2018; S. S. Rao & Go, 2010), and many patients with DEE often have limited 
mobility (A.T. Berg et al., 2020). The ketogenic diet, used as a treatment for intractable 
seizures in many DEE patients, as well as the use of enteral nutrition in DEE patients with 
feeding difficulties, are potential causes of GI symptoms (Bittencourt et al., 2012; Nei, 
Ngo, Sirven, & Sperling, 2014; Vezyroglou & Cross, 2016). Many anti-seizure medications 
are associated with adverse GI side-effects (Jahromi et al., 2011). Finally, many DEE 
patients have also been diagnosed with autism spectrum disorder (ASD) (Srivastava & 
Sahin, 2017), which is frequently accompanied with increased reports of GI symptoms, 
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with constipation being most common (McElhanon, McCracken, Karpen, & Sharp, 2014; 
Ofei & Fuchs, 2018). The etiology of the GI disturbances observed in ASD patients is not 
known; although, as with DEE patients, decreased physical mobility, diet, and side-effects 
of medications have been postulated as potential causes (McElhanon et al., 2014; Ofei & 
Fuchs, 2018). Conversely, there is anecdotal clinical evidence as well as animal studies 
suggesting that constipation can induce seizure activity (Moezi, Pirsalami, & Inaloo, 
2015). 
 
Ion channel gene-linked DEE variants may play direct roles in GI dysfunction. Voltage-
gated sodium (Nav) and potassium (Kv) channels are expressed in the mammalian GI 
tract, where they regulate the activity of enteric neurons and other excitable cells, thereby 
contributing to proper GI motility and fecal expulsion (Copel et al., 2013; Eijkenboom et 
al., 2019; Hatton et al., 2001; Hetz et al., 2014; Holm et al., 2002; Jepps et al., 2009; 
McKay, Ye, & Huizinga, 2006; Neshatian et al., 2015; O'Donnell et al., 2016; Osorio et 
al., 2014; Ou et al., 2002; Saito et al., 2009; Strege, Holm, et al., 2003; Strege, Ou, et al., 
2003). Thus, DEE-linked genetic variants may potentially directly affect GI function by 
causing aberrant GI cell excitability.  
 
There is an unmet clinical need to understand the mechanism(s) of GI symptoms in DEE. 
As a first step toward this goal, we used responses from a parent survey that included a 
large number of children with DEEs linked to variants in SCN1A, KCNB1, or KCNQ2 
(which encode for the voltage-gated ion channels, Nav1.1, Kv2.1, and Kv7.2, respectively) 
to uncover potential associations between the presentation of GI symptoms and known 
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risk factors for GI dysfunction: mobility, diet, medication, and ASD. An improved 
understanding of the factors and biological mechanism(s) underlying the recurring GI 
symptoms observed in DEE patients may lead to the development of novel treatments 









Survey design and participation  
An online parent-reported survey was performed using the CLIRINX® platform (Dublin, 
Ireland) and disseminated to families through several organizations including the Dravet 
Syndrome Foundation, the KCNB1 family group, and the KCNQ2 Cure Alliance. 
Caregivers of DEE patients of all ages were invited to participate. All survey data were 
collected through parent reports from June 2018 through February 2020. Parents were 
invited to upload their children’s genetic testing reports; however, we based inclusion of 
a child in this study on the parent’s affirmation that the child had a causative variant in 
one of the three ion channel genes of interest: SCN1A, KCNB1, or KCNQ2. Full methods 
for the survey have been previously described (A.T. Berg et al., 2020). The following 
provides a synopsis.  
 
Gastrointestinal (GI) symptoms  
Parents were asked to indicate whether their child had experienced specific GI 
symptoms—constipation, gut dysmotility or diarrhea—over the past month. They could 
also write in additional symptoms. As virtually all of the symptoms endorsed or reported 
were either constipation or dysmotility, and these two symptoms overlapped in all but a 
few cases, we simplified our primary outcome to the reporting of “constipation, dysmotility, 
or both” versus “neither”. For children with GI symptoms in the previous month, parents 
reported typical frequency (“daily”, “weekly”, “monthly”, or “less than once per month”) as 
well as whether the symptoms caused either discomfort or affected the child’s appetite 
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(“no”, “yes – occasionally but not a serious concern”, or “yes – common occurrence or 
serious concern”). Parents also reported if they had used any specific methods to alleviate 
the GI symptoms (supplements, enemas, medications). 
 
Potential risk factors associated with GI symptoms 
Parents provided information concerning functional mobility (for children ³ 2 years), 
dietary therapies, feeding tube usage, current anti-seizure medications, and diagnosis or 
features of autism. 
 
For mobility, we used the Gross Motor Functional Classification System (GMFCS) 
(Morris, Galuppi, & Rosenbaum, 2004). For analytic purposes, the GMFCS scale was 
condensed into three levels: “dependent” (scores of 4 or 5), walks but “requires aids” 
(score of 3), and “independent” (scores of 1 or 2). 
 
Parents were asked if their child had a feeding tube and, if so, whether their child was 
exclusively tube-fed or partially tube-fed. For children who ate by mouth (including those 
partially tube fed), parents indicated how often a child had difficulty chewing or 
swallowing. Choices were: “multiple times per meal”, “usually once per meal”, “not every 
meal but at least once on most days”, “not daily but usually a few times per week”, “less 
than once per week but every now and then”, or “almost never”.  These responses were 
condensed into the categories: “typically at least once per meal”, “typically more than 




Parents were also asked whether their child was currently being treated with a classic 
ketogenic, modified Atkins, or other special diet. 
 
Parents reported if their child had an ASD diagnosis or presented with features of ASD. 
Parents reported on the occurrence of seizures in the previous six months and whether 
bowel movements were considered by the parents to be a trigger for seizures.  
 
Finally, parents reported the child’s current use of 35 specific anti-seizure medications. 
For overall analysis of all three DEE cohorts, only medications being taken by 10 or more 
patients were considered. For individual analysis of each DEE cohort, only medications 
that were being taken by five or more patients were considered.  
 
Data analysis 
Statistical analyses were performed in SASÓ. Methods included Chi-square tests, 
Wilcoxon rank-sum analyses, and multiple logistic regression. Relative risks were used 
to quantify the strength of associations where appropriate. Results were considered 
significant at P < 0.05. 
 
IRB approval and informed consent  
All procedures for this study were approved by the Lurie Children’s Hospital IRB. Parents 









Of parents who enrolled in the study, 168 affirmed their child’s pathogenic variant in one 
of the three ion channel genes of interest, SCN1A (N=59), KCNB1 (N=31), or KCNQ2 
(N=78), and completed the survey portions about GI symptoms. Median patient age at 
the time of survey participation was 6.3 years (Interquartile Range: 3.3 to 10.3 years), 
and 55% of affected children were female (Table 2.1). The overall age distribution of DEE 
patients was: <5 (43%), 5-9 (30%), 10-15 (15%), ³ 16 years (12%). The children in 
KCNQ2-DEE group had a substantially younger age than those in the other two groups 
(P < 0.001). The sex distribution was similar across groups (P = 0.97; Table 2.1).  
 
 
Table 2.1: Demographic characteristics of DEE Cohorts 
 N SEX N (% FEMALE) MEDIAN AGE IN YEARS 
(IQR / RANGE)  
Total 168 92 (55%) 6.3 
(3.3 to 10.3 / 0.2 to 37.2) 
SCN1A-DEE (Dravet 
Syndrome) 
59 33 (56%) 8.1 
(4.8 to 16.3 / 0.4 to 37.2) 
KCNB1-DEE 31 17 (55%) 8.2 
(4.5 to 12.0 / 2.6 to 22.9) 
KCNQ2-DEE 78 42 (54%) 4.5 
(2.0 to 8.4 / 0.2 to 20.3) 
 
 
Most participants (127/168, 76%) were from North America, 27/168 (16%) were from 
Europe or the United Kingdom, and 14/168 (8%) were from other countries or did not 
specify. The majority of patients with DEE self-identified White or Caucasian (154/168; 
92%). Other reported races were Asian (9/168; 5%); American Indian, Alaskan Native, 
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First Nations (1/168; 0.005%); Black or African American (1/168; 0.005%), and Native 
Hawaiian or other Pacific Islander (1/168; 0.005%). Twelve (7%) parents reported that 
their child was of Hispanic or Latin ethnicity.  
 
Gastrointestinal symptoms 
Overall, 92/168 (55%) parents reported constipation or dysmotility in their child. The 
prevalence of GI symptoms differed significantly across the three epilepsy groups (Table 
2.2). Despite the similar distributions of males and females between the three cohorts 
(Figure 2.1A), GI symptoms were not clearly associated with sex (P = 0.08). We explored 
sex differences within each DEE group and found, within the SCN1A-DEE cohort, a 
substantial association between GI symptoms and sex [20/33 (61%) female SCN1A-DEE 
patients versus 6/26 (23%) male patients, (P = 0.004; Figure 2.1B)]. No such association 
was apparent in the other two DEE groups. Despite age differences across the DEE 
groups, the age distributions of patients with and without GI symptoms were very similar 
with median ages of 6.2 and 6.3 years, respectively (Figure 2.1C). Furthermore, after 
adjustment for DEE type, patient age was not significantly associated with the 






Figure 2.1: Sex and age distributions of patients with reported GI symptoms (GI-
SX+) and those with no reported GI symptoms (GI-SX-) within SCN1A-, KCNB1-, or 
KCNQ2-DEE cohorts. (A) The distribution of females and males did not significantly 
differ overall between the GI-SX+ and GI-SX- patient groups. (B) There were 
proportionally more females than males with GI symptoms within the SCN1A cohort, but 
there were no significant differences between the proportions of males and females with 
GI symptoms in the KCNB1 or KCNQ2 cohorts. (C, D) The age distribution did not 
significantly differ between GI-SX+ and GI-SX- patient groups in any of the three cohorts. 
** = P < 0.01.  
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Most parents (86/92) who reported GI symptoms in their children also provided 
information on how frequently these symptoms manifested. Survey responders reported 
either daily or weekly symptoms in 63/86 (73%) DEE patients, overall. Daily or weekly 
symptoms were reported in 15/25 (60%) SCN1A-DEE patients, 8/11 (73%) KCNB1-DEE 
patients, and in 40/50 (80%) KCNQ2-DEE patients (Table II).  
 
Patient discomfort, stemming from the GI symptoms, was considered a common 
occurrence or serious concern in 29/92 (32%) affected patients (Table II). In a post-hoc 
comparison, SCN1A-DEE patients were significantly less likely than KCNB1- and 
KCNQ2-DEE patients (combined) to experience common or serious discomfort as a result 
of their GI symptoms (P = 0.02). Parent-reported changes to appetite due to GI symptoms 
was a common occurrence or serious concern for 13/91 (14%) of responders (Table 2.2). 
KCNB1-DEE patients were marginally more likely to experience appetite disturbances as 
a consequence of GI symptoms, compared to the other two groups (P = 0.06).  
 
Multiple treatments were utilized by parents to relieve the GI symptoms; 40/92 (43%) 
reported using including dietary supplements, 19/92 (21%) reported using enemas, 44/92 













GI symptom prevalence (26/59) 44% (11/31) 35% (55/78) 71% P < 0.001 




% <1 day/month 
 
(4/25) 16%  
(11/25) 44%  
(5/25) 20%  
(5/25) 20%  
 
 
(2/11) 18%  
(6/11) 55%  
(2/11) 18%  
(1/11) 9%  
 
(18/50) 36%  
(22/50) 44%  
(9/50) 18%  
(1/50) 2% 
P = 0.14 
GI symptom effects 
% discomfort 
[a] % Yes, common 
occurrence/serious 
concern 
[b] % Yes, occasionally 
but not a serious 
concern 
  
% appetite disturbances 
[a] % Yes, common 
occurrence/serious 
concern 
[b] % Yes, occasionally 
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     (4/11) 36% 
 
          





     (4/10) 40% 
 
 




     (22/55) 40% 
 
         





      (7/55) 13% 
 
              
    (25/55) 45% 
 
 








P = 0.10 
Functional mobility 
% dependent  















P < 0.001 
Ketogenic diet (KD) 
% currently using KD  










P = 0.13 
Gastrostomy tube 
% exclusive  















P = 0.28 
Chewing/swallowing 
difficulties 
% every meal 
% daily 
% weekly 
% <1 day/week 
 
(8/57) 14%  
(2/57) 4%  
(7/57) 12%  
(40/57) 70%  
 
(0/26) 0%  
(5/26) 19%  
(4/26) 15%   
(17/26) 66%  
 
 
(14/64) 22%  
(17/64) 26%  
(5/64) 8%  
(28/64) 44%  
P = .0018 
Autism diagnosis/features (30/59) 51% (15/31) 48% (27/70) 39% P = 0.35 





Mobility limitations and GI symptoms 
The distribution of functional mobility scores differed significantly across the three cohorts 
(Table 2.2). However, using multiple logistic regression to control for the effect of 
individual DEEs, we found no overall association between functional mobility and 
presence of GI symptoms (P = 0.47, Figure 2.2A). Notably, although KCNQ2-DEE 
patients exhibited both the lowest functional mobility scores (P < 0.001) as well as the 
highest prevalence of GI symptoms among the three cohorts, within the KCNQ2-DEE 
group, there was no significant association between mobility scores and GI symptoms (P 
= 0.23).  
 
Ketogenic diet and GI symptoms 
In total, 9/160 (6%) children were reported to be currently treated with the ketogenic diet 
(Table 2.2. On bivariate analysis, use of the ketogenic diet was not associated with GI 
symptoms (P = 0.14); however, after adjustment for DEE, use of ketogenic diet was 
significantly associated with GI symptoms (P = 0.03). This change appears to be due to 
a finding in the KCNB1 cohort; all children in that group who were using the ketogenic 
diet also had GI symptoms (Figure 2B). 
 
Gastrostomy tube and GI symptoms 
Current partial or exclusive use of a gastrostomy tube was reported in 21/160 (13%) DEE 
patients and did not differ significantly between DEE groups (Table II). After adjusting for 
DEE, use of gastrostomy tube was found to be significantly associated with GI symptoms 
(P = 0.03; Figure 2C).  
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Chewing and swallowing difficulties and GI symptoms 
Excluding patients who were exclusively tube-fed, frequent (occurring at least once per 
meal) difficulties with chewing or swallowing were reported for 22/147 (15%) DEE patients 
(Table II). The frequency of reported chewing or swallowing difficulties varied significantly 
across the three DEE groups (Table II), with KCNB1-DEE patients significantly less likely 
to have chewing or swallowing difficulties (P = 0.003). After adjusting for DEE, chewing 
and swallowing difficulties were not associated with reports of GI symptoms (P = 0.52; 
Figure 2D).  
 
Autism spectrum disorder (ASD) and GI symptoms 
Either a diagnosis or having features of ASD was reported in 72/160 (45%) DEE patients; 
this did not vary across the three DEE groups (Table II). After adjusting for DEE, there 
was no significant association between reported ASD diagnosis or features and GI 
symptoms (P = 0.08; Figure 2.2E). 
 
Seizures and GI symptoms 
While seizure prevalence in the previous six months differed significantly between the 
different DEE groups (Table 2.2), there was no correlation between seizures and GI 
symptoms after adjusting for DEE type (P = 0.99; Figure 2.2F). Overall, 15/135 (11%) 
patients were reported to have bowel movements as a seizure trigger, and DEE patients 
with GI symptoms were significantly more likely to report seizures triggered by bowel 




Figure 2.2: Distributions of SCN1A-, KCNB1-, or KCNQ2-DEE patient functional 
domains in patient groups with (GI-SX+) and without (GI-SX-) GI symptoms. Parents 
reported information regarding the (A) degree of independent mobility, (B) current use of 
a special diet, (C) relative reliance on a gastrostomy tube for feeding, (D) frequency of 
chewing and/or swallowing difficulties, (E) autism spectrum disorder (ASD) diagnosis or 





Anti-seizure medications and GI symptoms 
Overall, no individual medication appeared to be linked with GI symptoms across the 
three DEE groups (Figure 2.3A). In exploratory analyses within each cohort (Figure 2.3B); 
we found stiripentol, a drug specifically approved for Dravet syndrome, was significantly 
associated with increased report of GI symptoms in SCN1A-DEE patients (P < 0.001). 
We also found a significant association between cannabidiol (CBD) and GI symptoms in 








Figure 2.3: Incidence of GI symptoms in SCN1A-, KCNB1-, or KCNQ2-DEE patients 
taking antiseizure medications. Relative risks ratios with 95% confidence intervals were 
calculated for (A) medications being taken by > 10 patients across all three disease 
cohorts as well as (B) medications being taken by ³ five patients within each respective 
DEE cohort. Higher relative risk values are associated with an increased incidence of GI 









Children with ion channel-gene-linked DEEs have a high prevalence of GI symptoms, 
specifically constipation and dysmotility, which do not appear to be explained by common 
risk factors that frequently arise in the DEE population, such as limited functional mobility, 
anti-seizure medications, or presence of ASD. These symptoms create additional needs 
for medical care, place burdens on parents and caregivers, and negatively impact the 
quality of the patients’ lives.  
 
By initially focusing on DEE patients with variants in the genes encoding a subset of Nav 
and Kv channels, we have documented the prevalence and risk factors for GI symptoms 
in channelopathy-linked DEE patients. Although we have no direct comparison to the 
frequency of similarly reported GI symptoms in a healthy population, a meta-analysis of 
18 independent studies reporting on constipation in the general population found a 
median prevalence of constipation in children of ~9% (Interquartile Range: 5% to 17%), 
with the highest estimate being 30% (van den Berg, Benninga, & Di Lorenzo, 2006). 
These estimates from population-based studies are well below our overall finding of 55% 
(95% Confidence Interval: 47% to 62%) prevalence in DEE patients. Our findings 
emphasize the prevalence and severity of GI symptoms in channelopathy-associated 
DEE patients over a broad range of ages, while highlighting potential differences between 




While this study is focused on channelopathies, it is important to note that GI symptoms 
are prevalent in multiple DEEs. We further considered reports of GI symptoms from two 
non-channelopathy, gene-specific cohorts who had participated in a similar survey with 
the same questions regarding GI symptoms (in review). Parents of 71 CHD2- and 
PACS1-linked DEE patients reported rates of constipation and gastric dysmotility in their 
children, and the average prevalence of these symptoms across these two groups was 
39%, which was lower than the average prevalence of GI symptoms, 55%, reported for 
the channelopathy groups (N = 159, consisting of SCN1A-, KCNB1-, and KCNQ2-linked 
DEE patients) (P = 0.03). Though relatively little is known about the role of the CHD2 and 
PACS1 genes in GI function, it is interesting to note that CHD2 variants have been 
identified in multiple human gastric and colorectal cancers (M. S. Kim, Chung, Kang, Yoo, 
& Lee, 2011). Future research could determine if the GI symptoms in the CHD2- and 
PACS1-linked DEEs are similarly not explained by common risk factors often exhibited 
by DEE patients. 
 
Risk factors for GI symptoms are common in the DEE population and include mobility 
limitations, ketogenic diet, and medications. None of these, however, appeared to be a 
major driving factor behind the prevalent GI symptoms in our DEE cohorts. For example, 
the KCNQ2-DEE patients were the least mobile group and exhibited the highest 
proportion of GI symptoms. Yet, within the KCNQ2-DEE cohort, there was no association 
between degree of mobility and GI symptoms. Further, there was no overall association 
between GI symptoms and mobility after adjusting for DEE type. Small, borderline 
associations were observed for well-known risk factors such as gastrostomy tube usage 
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and ketogenic diet therapy. As so few children had these interventions, their presence 
does not explain the high reported prevalence of GI symptoms in our study patients. 
Interestingly, sex was significantly associated with reported GI symptoms in SCN1A-, but 
not KCNQ2- or KCNB1-DEE patients; females with SCN1A-linked DEE were about three 
times as likely as their male counterparts to have these symptoms. Though females are 
more likely than males to develop chronic constipation in the general population 
(Johanson, Sonnenberg, & Koch, 1989), this differential was not apparent in the two other 
DEE groups. Independent replication of the finding is needed, but it could reflect sex-
specific aspects of channelopathy pathophysiology. 
 
Though previous research suggests a connection between bowel movements and seizure 
activity (Moezi et al., 2015), we observed no statistically significant association between 
GI symptoms and recent seizure activity in these channelopathy cohorts. In a separate 
part of the survey in which seizure triggers were queried, only a small percentage of 
parents reported bowel movements as a seizure trigger. Future studies could look more 
broadly at potential correlations between these symptoms in multiple forms of pediatric 
epilepsies.  
 
Multiple anti-seizure medications are used in patients with DEEs, and these medications 
are known to have a wide range of side-effects, including GI dysfunction. While we are 
very cautious not to over-interpret our findings due to the small numbers, reporting use of 
any one medication and the multiple hypotheses tested, a few findings may inform new 
hypotheses to test formally in future studies. Stiripentol, a drug approved exclusively for 
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Dravet syndrome, was significantly associated with GI symptoms in the SCN1A-DEE 
group. GI symptoms were also correlated with cannabidiol (CBD) use in KCNB1-DEE 
patients only. Unlike stiripentol, CBD was taken by multiple children from all three DEE 
cohorts. Whether this particular finding for CBD reflects a specific effect on GI function in 
the context of Kv2.1 channel impairment remains to be seen. 
 
The prevalence of GI symptomology in DEEs linked to variants in SCN1A, KCNB1, or 
KCNQ2 is not well-explained by common risk factors for GI dysfunction and raises the 
question of whether the proteins encoded by these genes may contribute to proper GI 
tract function. SCN1A gene expression has been localized to the human colonic 
myenteric plexus, the branch of the enteric nervous system that controls bowel motility 
(Hetz et al., 2014). A study in mice found that mechanosensitive colonic fibers express 
Nav1.1 (Osteen et al., 2016). While gastrointestinal expression of KCNB1 and KCNQ2 in 
humans is not well-characterized, Kv2.1 was found to be localized to murine colonic 
myenteric plexus (Seifi et al., 2014), and Kv7 channels have been localized to intrinsic 
neuronal populations as well as smooth muscle in the human GI tract (Peiris et al., 2017). 
Functionally, Kv7 channels are thought to be important for controlling contractile activity 
in the murine intestinal tract (Jepps et al., 2009) as well as mediating sensory colonic 
afferent responses to noxious stimuli in mice and humans (Peiris et al., 2017). 
Importantly, a wide variety of voltage-gated ion channel-encoding genes that are known 
to be expressed in the GI tract, in addition to brain, have been linked to various diseases, 
including other DEEs, that manifest with GI symptomology (Table III). GI symptoms in 
channelopathy-associated DEEs are common, serious, but poorly understood 
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comorbidities of these DEEs. The next steps will entail investigating the mechanisms and 
elucidating the roles of GI-expressed ion channels in GI function and dysfunction. The 
combination of our survey results and published data, suggest DEE-linked voltage-gated 
ion channel gene variants may also contribute to the GI dysmotility and constipation 
commonly reported in patients and lay the groundwork for future mechanistic studies in 
animal models of DEE. 
 
Understanding the clinical condition is essential for guiding future investigations into the 
mechanisms by which variants in DEE-linked genes, particularly those encoding voltage-
gated ion channels and other proteins with established links to GI function and 
dysfunction, may directly contribute to GI pathology via alterations in GI cell functionality 
or the development and activity of the enteric nervous system. As precision medicine 
becomes increasingly more feasible, gene-editing therapeutics could more directly 
elucidate the involvement of these proteins in specific DEE comorbidities, such as GI 
symptoms.  
 
Several limitations must be acknowledged. First, the data presented in this study are 
derived from parent reports. This includes the diagnosis of specific ion channel variants 
linked to each child’s DEE, although several parents provided genetic testing reports that 
corroborated the etiology. Because the families were recruited through groups that were 
specific to their child’s disease, we expect any error in reporting for etiology to be minimal. 
In addition, the exact description of GI symptoms alone may not have been sufficiently 
specific and may have reflected how such questions are asked in a simple review-of-
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systems often performed in a medical office. Additional questions regarding frequency, 
discomfort, and impact on appetite helped to define the scope of and contextualize the 
problem in the children’s and parents’ daily lives. Information about potential risk factors 
for GI symptoms was also obtained by report; however, the information was appropriate 
for obtaining in this manner. For functional mobility, we utilized the GMFCS, which has 
been previously validated for parent report (Morris et al., 2004). Other questions were 
developed in collaboration with parents and based on review of similar measures 
available throughout the literature. Finally, some questions were straightforward checklist 
items, such as whether a child had a gastrostomy tube or was being treated with the 
ketogenic diet. We also acknowledge that this survey was disseminated to an unknown 
number of people. We therefore cannot be certain that the responses of our 168 parent 
respondents can be extrapolated to the general population of children with DEEs. 
Notably, this is often the case in studies of rare diseases. The use of a web-based survey, 
however, did permit us to reach a large number of people, much greater than would have 
been possible in a single or even multi-center study over a relatively brief period of time. 
Some of our comparisons, particularly medications, were exploratory. We had the 
opportunity to ask these questions but often did not have the statistical power to address 
them. Further, the number of medications reported would reasonably raise concerns 
regarding multiple hypothesis testing. Thus, these results should be considered 
hypothesis-generating only. In this survey, we only directly asked about current use of 
medications for treatment of seizures and GI symptoms. We therefore do not have 
information on other medications with potential GI side-effects that may be used by 




In conclusion, this work provides novel information that highlights the importance of GI 
dysfunction in the DEEs and suggests these GI symptoms may be part of the disease 
itself and not just a result of poor mobility, medications, or other factors. Elucidating the 
role of ion channel dysfunction in GI symptoms for patients with DEE may guide future 










Chapter 3 : Colonic Myenteric Neuron Dysfunction in a Mouse Model 
of SCN1B-linked Developmental and Epileptic Encephalopathy 
 
Veronica Beck (VB) conducted the majority of data collection and all data analysis for 
Figure 3.1. VB contributed to data collection and performed the majority of data analysis 
for Figure 3.2. VB contributed to data collection and data analysis for Figure 3.3. VB 
completed all data collection and the majority of analysis for Figure 3.4, all data collection 
for Figure 3.5, and assisted with data analysis for Figure 3.6. Kathleen Ignatoski and 
Vinodh Balendran contributed to data collection for Figure 3.1D. Larissa Robinson-
Cooper and Dennis Claflin contributed to data collection and analysis of Figure 3.2. 
Caroline Scheuing and Samantha Hodges contributed to data collection and analysis for 
Figure 3.3. Carter Dunaway performed data analysis for Figure 3.4D and all data analysis 
for Figure 3.5. Alberto Perez-Medina performed all data collection and the majority of data 
analysis for Figure 3.6. Experiments presented were performed in the laboratories of 
Susan Brooks, William Birdsong, and Lori Isom at the University of Michigan. Additional 
training was provided by Narayana Krishna Yelleswarapu in the laboratory of James 








The enteric nervous system (ENS) is a complex neuronal network, located within the 
gastrointestinal (GI) tract, that controls the gut motility mechanisms necessary for proper 
digestion and excretion. GI motility is controlled by the myenteric plexus, which consists 
of neurons that communicate with GI smooth muscle cells to regulate contractions and 
relaxations. While the ENS is capable of functioning independently of central nervous 
system (CNS) input, mechanisms that control neuronal excitability and axonal 
pathfinding within the ENS are often analogous to those that govern neuronal excitability 
and connectivity in the CNS. Thus, it is not surprising that a growing body of clinical 
evidence shows that neurological diseases often present with comorbid abnormalities in 
the GI tract. Here, we investigate a potential mechanism underlying ENS dysfunction 
common to neurological diseases: altered activity of voltage-gated sodium channels 
(VGSCs) – which control the generation and propagation of action potentials in CNS and 
ENS neurons – and VGSC b1/b1B subunits, which modulate VGSC plasma membrane 
trafficking, gating, and voltage-dependence as well as participate in axonal pathfinding 
and fasciculation.  
 
VGSC gene variants, including variants in SCN1B, encoding the VGSC b1/b1B subunits, 
are linked to both developmental and epileptic encephalopathies (DEEs) as well as GI 
motility disorders. Furthermore, DEE patients often exhibit constipation, suggesting a 
connection between altered VGSC function and aberrant motility of the colon, resulting in 
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decreased rates of excretion of fecal material. The goal of this project was to gain insight 
into how loss-of-function (LOF) DEE variants in SCN1B contribute to colon dysmotility by 
studying the Scn1b-null mouse model of DEE. Our results show that Scn1b-null mice 
exhibit colonic dysmotility, which is driven by increasingly reduced and dysregulated 
colonic motility in line with disease progression. Furthermore, our data suggest that the 
mechanism driving this phenotype includes aberrant transcriptional regulation of voltage-
gated ion channel genes that are necessary for proper enteric neuron excitability and 
signaling to effector SMCs. The results of this work may inform the mechanism of GI 
symptomology observed in SCN1B-linked DEE patients as well as in patients suffering 






Voltage-gated sodium channels (VGSCs), which control action potential initiation and 
propagation in excitable cells, are critical for normal activity of neurons (Beyder & 
Farrugia, 2012; Catterall, 2012; Chahine et al., 2008; Edokobi & Isom, 2018; O'Malley & 
Isom, 2015; J. Wang, Ou, & Wang, 2017). VGSCs consist of one pore-forming a subunit 
and two flanking b subunits (Catterall, 2000; Isom et al., 1992; Morgan et al., 2000; 
O'Malley & Isom, 2015; Yu et al., 2003). In the central nervous system (CNS) and 
peripheral nervous system (PNS), the VGSC b1 subunit and its soluble splice variant, 
b1B, – both encoded by SCN1B – modulate sodium and potassium current, chaperone 
VGSC a subunits to the plasma membrane, influence axon fasciculation and pathfinding, 
and regulate the transcription of VGSC and other voltage-gated ion channel (VGIC) genes 
(Aeby et al., 2019; Bouza et al., 2021; Brackenbury et al., 2010; Brackenbury et al., 2008; 
Brackenbury & Isom, 2011; Davis et al., 2004; Hull et al., 2020; Lopez-Santiago et al., 
2011; Patino et al., 2009; Patino & Isom, 2010; Yuan et al., 2019). These previous studies 
illustrate the importance of VGSC b1 subunits in normal nervous system excitability and 
development; however, their role in a specific subset of PNS neurons – the enteric 
nervous system (ENS) located in the gastrointestinal (GI) tract – is unknown. Here, we 
examine the role of VGSC b1 subunits in ENS function as well as their effects on GI 
motility. 
 
Variants in VGSC-encoding genes, including SCN1B, have been linked to numerous 
neurological diseases, including developmental and epileptic encephalopathy (DEE) and 
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generalized epilepsy with febrile seizures plus (GEFS+) (Aeby et al., 2019; Chahine et 
al., 2008; Kaplan et al., 2016; O'Malley & Isom, 2015). Notably, chronic or severe 
constipation is frequently reported in case studies of DEE patients with variants in VGSC-
associated genes, suggesting impaired GI motility in these patients (Al-Mehmadi et al., 
2016; Beck et al., 2021; Berecki et al., 2018; de Kovel et al., 2014; Gardella & Møller, 
2019; Gay et al., 2008; Howell et al., 2015; Leipold et al., 2013; Villas et al., 2017; Ziobro 
et al., 2018). These clinical findings show that gene variants impacting VGSC function 
often produce both neurological and GI symptomology, predicting comorbid dysfunction 
of neurons in the CNS and ENS in VGSC-linked DEEs.  
 
The mechanisms required for proper colon motility are largely  controlled by the activity of 
the myenteric plexus, one of the two branches of the ENS, that is situated between the 
internal circular muscle and external longitudinal muscle layers of the intestinal wall 
(Furness et al., 2014; Hansen, 2003). This localized network of thousands of ganglia is 
interconnected by nerve fiber bundles, and the myenteric neurons also innervate 
interstitial pacemaker cells and effector smooth muscle cells (SMCs) in both the circular 
and longitudinal muscle layers to coordinate contractions and relaxations (Furness, 2000; 
Hansen, 2003; Iino & Horiguchi, 2006; Schneider et al., 2019).  
 
VGSC a and b1/b1B subunit genes and/or their protein products are expressed by 
multiple excitable cell types in the mammalian GI tract, including SMCs, interstitial 
pacemaker cells, and myenteric neurons (Bartoo et al., 2005; Hetz et al., 2014; C. S. Hirst 
et al., 2015; Holm et al., 2002; O'Donnell et al., 2016; O'Donnell et al., 2019; Osorio et 
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al., 2014; Sage et al., 2007; Strege, Ou, et al., 2003). The VGSCs Nav1.5 and Nav1.9 – 
encoded by Scn5a and Scn11a, respectively – have been found to influence enteric 
neuron activity and subsequent GI motility patterns in mice (Copel et al., 2013; Osorio et 
al., 2014; Padilla et al., 2007). Likewise, variants in SCN5A and SCN11A have been 
linked to GI pathology in humans (Beyder et al., 2014; Neshatian et al., 2015; O'Donnell 
et al., 2016; Saito et al., 2009; Strege et al., 2018; Woods et al., 2015). VGSC b1 subunits 
are known to modulate the cell-surface expression and activity of Nav1.5 and Nav1.9 in 
mice; Scn1b-null cardiac myocytes exhibit increased Nav1.5 expression and sodium 
current, and dorsal root ganglion (DRG) neurons exhibit decreased cell-surface Nav1.9 
expression (Brackenbury et al., 2010; Lin et al., 2015; Lopez-Santiago et al., 2011; Lopez-
Santiago et al., 2007). Furthermore, a recent study found reduced SCN1B mRNA levels 
in in both ganglionic and aganglionic portions of colon in patients with Hirschsprung’s 
disease, a GI disorder characterized by atypical ENS development and subsequent 
colonic dysmotility (O'Donnell et al., 2019). These data support a role of VGSC b1 
subunits in the constipation experienced by VGSC-linked DEE patients.  
 
To determine the contribution of SCN1B to the regulation of ENS activity and 
development in colon, we analyzed colonic motility patterns as well as myenteric plexus 
structure, activity, and VGIC gene expression in Scn1b-null mice, a mouse model of 
SCN1B-linked DEE (DEE52). We observed colonic dysmotility in Scn1b-null mice, 
mirroring the constipation observed in DEE patients. Functional experiments revealed 
irregular stretch-induced colonic contractions in Scn1b-null mice, likely driven by 
uncoordinated activity of myenteric neurons. We found myenteric neuron size, density, 
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and subtype ratios to be normal in Scn1b-null mice; furthermore, stimulus-induced 
signaling from myenteric neurons to SMCs was intact. Scn1b-null mice exhibited aberrant 
inter-ganglionic connectivity as well as age-dependent alterations in VGIC gene 
expression, which may explain the dysmotility. This work predicts multiple roles for VGSC 
b1/b1B subunits in ENS and suggests how loss-of-function (LOF) SCN1B variants may 
contribute to the GI dysfunction observed in DEE52 patients as well as in patients suffering 






Scn1b-null and WT mice were generated from Scn1b+/− mice as described (Chen et al., 
2004). Scn1b+/− mice were maintained on the C57BL/6J background for over 20 
backcrossed generations and are thus congenic. To generate Scn1b-null and WT mice 
with the Chat gene labeled with an endogenous green fluorescent protein (GFP) epitope 
tag. Scn1b+/− mice were crossed with ChAT−eGFP mice that express eGFP in choline 
acetyltransferase (ChAT)-expressing neurons, received from Dr. G. Richerson at the 
University of Iowa (Y. Wu et al., 2019). Male and female animals ages postnatal day (P) 
13-17 were used in all experiments. Animals were housed in the Unit for Laboratory 
Animal Medicine at the University of Michigan. All procedures adhered to NIH guidelines 
and were approved by the University of Michigan Institutional Animal Care and Use 
Committee. 
 
Table 3.1: Primary and secondary antibodies used in Chapter 3 experiments 
Primary Antibody Host Dilution  Source Catalog # 
ANNA-1(HuC/D) Human 1:10,000 Human anti-sera 
(Vanda Lennon, Mayo 
Clinic, Rochester, MN) 
 
nNOS Rabbit 1:200 ThermoFisher Scientific 61-7000 
Tubulin b3 (clone TUJ1)  Mouse 1:200 BioLegend 801202 
 
Secondary Antibody Dilution  Source Catalog # 
AlexaFlour® goat anti-human 594 nm 1:500 ThermoFisher Scientific A-11014 
AlexaFlour® goat anti-rabbit 647nm 1:500 ThermoFisher Scientific A-32733 







Table 3.2: Drugs used in Chapter 3 experiments 
Drug Concentration 
used 
Source Catalog # Mechanism 
Bethanechol 
Chloride 

































100 µM Sigma-Aldrich N5501-16 Nitric oxide 
synthase 
inhibitor 





Behavioral video observation 
Two age-matched, genotype-matched littermates were observed in a static housing cage 
with gel chow (details) for 35 minutes. In each pairing, one mouse was marked with tape 
to differentiate individuals for future analysis. Videos were recorded using OmniPlex D 
software and hardware acquired from Plexon Inc. in Dallas, Texas, USA. Cameras were 
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oriented to provide full field of view of the chow. Each video was observed and analyzed 
manually. “Feeding” was defined as licking, biting, or chewing the gel food. Total fecal 
pellets expelled during the observation period were counted at the end of the 35-minute 
observation period; additionally, total fecal pellets observed at the bottom of the 
observation cage were counted at the end of the experiment. 
 
 
Gastric bead assay 
To assess colon motility, we inserted a glass bead (1.2 mm in diameter) ~1 cm into the 
distal colon of Scn1b-null and WT mice using a lubricated pipette tip and timed bead 
expulsion. 
 
Immunohistochemistry tissue preparation 
Mice were anesthetized using isofluorane then euthanized via decapitation, and distal 
colon was dissected into 4°C 1X Krebs solution (117 mM NaCl, 4.7mM KCl, 2.5 mM 
CaCl2, 1.2 mM MgCl2, 1.2 mM NaH2PO4, 25 mM NaHCO3, and 11 mM dextrose) and 
flushed of fecal contents. The colon tissue was then prepared for cryosections or whole 
mounts. 
Cryosections: Dissected colon tissue was fixed for two hours in 4% 
paraformaldehyde at room temperature, washed 3 times for 10 minutes with 1X 
phosphate-buffered saline (PBS) then cryoprotected in 30% sucrose overnight at 4°C. 
Tissues were then embedded in O.C.T. (Tissue-Tek), and 8 μm sections were cut on a 
Leica cryostat and stored at −20 °C until processing for immunohistochemistry. For distal 
muscle thickness analysis, mounted on slides using ProLong Gold anti-fade reagent with 
DAPI (Life Technologies), cover slipped, and stored in at 4°C until imaging. For distal 
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colon circumference and muscle area measurements, hematoxylin and eosin staining of 
cyrosections was performed by the University of Michigan Rogel Cancer Center Tissue 
and Molecular Pathology Shared Resource. 
Whole mounts: Dissected distal colon tissue was pinned to a Sylguard silicone 
coated petri dish with mucosa facing up and fixed overnight in 4% paraformaldehyde at 
4°C. The tissue was then washed 3 times for 10 minutes with 0.1M phosphate buffer (PB) 
solution. Whole-mount longitudinal muscle myenteric plexus preparations (LMMPs) were 
achieved via removal of the mucosa, submucosal plexus, and circular muscle layers of 
the tissues by microdissection. The samples were then bathed in blocking buffer (4% goat 
serum, 0.4% Triton X-100 in 0.1% PB) for one hour and then incubated with primary 
antibodies (diluted in blocking buffer) overnight at 4°C and washed 3 times for 10 minutes 
with 0.1M PB. From this point all steps were performed in the dark to minimize 
photobleaching of secondary antibodies. Samples were incubated with secondary 
antibodies (diluted in blocking buffer) for 2 hours, washed 3 times for 10 min in 0.1M PB, 
then mounted on slides using ProLong Gold anti-fade reagent with DAPI (Life 
Technologies), cover slipped, and stored in at 4°C until imaging.  
 
Confocal microscopy and analysis 
Slides were imaged on a Zeiss LSM 880, located in the University of Michigan Department 
of Pharmacology, with a 20X objective or 63X oil objective, and excitation was 
accomplished using 405, 488, 561, and 633 nm lasers. Images consisted of maximum 
intensity projections of z-stacks (optical section width automatically calculated by Zeiss 
Zen software based on tissue thickness and channel quantity: 20X images were acquired 
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at 1.26 µm intervals for sections with three layers of fluorescence and at 1.07 µm intervals 
for sections with four layers of fluorescence, while 63X images were acquired at 0.44 µm 
intervals for sections with three layers of fluorescence and at 0.43 µm intervals for 
sections with four layers of fluorescence. Images were analyzed manually using Zeiss 
Zen software and ImageJ. Unless otherwise specified, 4 to 10 randomly selected fields 
per sample were analyzed for all quantifications.  
Quantitative analysis of enteric neuron density and size: Using whole mount-
stained samples, we counted the number of enteric neurons (ANNA-1+ cells) to determine 
density. Enteric neuron subtype proportions were quantified by counting the number of 
ANNA-1+, eGFP+ (indicating ChAT+ cells), and nNOS+ cells. For size analysis, the FIJI 
StarDist plugin (Schmidt, Weigert, Broaddus, & Myers, 2018) was utilized to automatically 
measure soma area. Imaging and analysis were performed blind to genotype. 
Quantitative analysis of axonal networks. Clusters of neurons labeled with nNOS, 
TUJ1, or ChAT-eGFP were labeled as distinct ganglia on ImageJ. Connections between 
two ganglia were deemed primary axonal connections. Axonal connection length was 
measured by drawing a segmented line between each axon's ganglia-contact points. 
Width was measured at the middle-most point of each axonal connection. Any 
distortions in the image were excised to provide a more accurate area measurement. 
Additionally, within a single image the ChAT-eGFP fluorescence layer was often 
merged with the TUJ1 or nNOS fluorescence layer to better visualize connections. 
 
Organ bath 
Dissected distal colon segments were flushed with 1X Krebs solution and mounted with 
10-0 monofilament nylon ligatures on both ends between a stationary attachment point 
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and an isometric force transducer (Aurora Scientific, model 400A). The chamber was then 
mounted on the stage of an inverted microscope (Zeiss Axiovert 100) and perfused with 
37°C 1X Krebs solution at a flow rate of 3 solution changes/min. A resting tension of 0.2 
grams was applied to each tissue preparation. Baseline contraction patterns were 
recorded over 30 minutes. Electrical stimulation was delivered via platinum plate 
electrodes placed on either side of and parallel to the colon segment. The electrical 
stimulation paradigm consisted of a 20 Hz train of pulses, 0.5 ms pulse duration, with train 
durations of 500 ms. Stimulus intensity was 40-70mA, controlled using a high-power 
stimulator (Aurora Scientific, model 701C) operating in constant-current mode. All drug 
concentrations listed in Table 6. Bethanechol chloride and sodium nitroprusside (SNP) 
were added into each bath sequentially to produce maximal contraction and relaxation 
responses, respectively. The tissue was then stimulated using an electrode at increasing 
intensities until a stimulation intensity was reached that elicited reproducible relaxation 
and contraction responses from the tissue. Tetrodotoxin (TTX) was then added to block 
neuromuscular transmission in order to reveal myogenic responses and ensure that the 
chosen intensity of the transmural electrical stimulus was specifically exciting enteric 
neurons in the distal colon segment. The colon segments were repeatedly stimulated 
during the TTX condition to ensure that the contraction events that emerged in the 
presence of TTX were not neuronally mediated. MRS 2179 was administered to block 
purinergic-mediated muscle relaxation to reveal the nitrergic component of relaxation, 
mecamylamine was administered to block cholinergic signaling to myenteric neurons, 
scopolamine was administered to block cholinergic signaling to smooth muscle, and nitro-
L-arginine (NLA) was administered to block nitrergic-mediated muscle relaxation to reveal 
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the purinergic component of relaxation. Raw force traces were acquired using a digital 
oscilloscope (Teledyne-LeCroy, model HDO6034A).  
Quantitative analysis of tissue contractions and relaxations. Traces were analyzed 
off-line using digital signal processing software (Signo, Alameda Applied Sciences). To 
distinguish distension-induced peristaltic contractions from intrinsic myogenic patterns, 
we only analyzed contraction events that measured at least twice the amplitude of a 
tissue’s baseline tension.  
 
Intracellular recordings of excitatory and inhibitory junction potentials at the circular 
smooth muscle  
 
Dissected distal colon tissue was pinned to a Sylguard silicone-coated petri dish with 
mucosa facing up, and muscosal and submucosal layers were then removed by 
microdissection to expose the circular smooth muscle layer. A 0.5 cm2 section was then 
transferred to a 5 ml silicone elastomer-lined recording chamber. Tissues were gently 
stretched and pinned to the recording chamber with small stainless-steel pins. The 
chamber was then mounted on the stage of an inverted microscope and perfused with 
37⁰C 1X Krebs solution at a flow rate of 4 ml/min. To limit spontaneous muscle 
contractions during intracellular recordings, the L-type VGCC antagonist nifedipine was 
added to the perfusing Krebs solution for the duration of each experiment. The 
preparations were allowed to acclimate for 30 minutes. Borosilicate 1.0 mm x 0.5 mm ID 
w/fiber glass (FHC Inc., Bowdoin, ME) microelectrodes were filled with 2M KCl (tip 
resistance, 60-120 MΩ) and were then used to impale circular smooth muscle cells. Focal 
stimulation was performed using a FHC tungsten metal bipolar electrode (2-3 mΩ) in the 
recording chamber. The electrodes were connected to a Grass S88 stimulator and 
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stimulus isolator constant current unit (Grass Technologies, West Warwick, RI). The 
electrical stimulation paradigm consisted of a 10 Hz train, 0.5 ms pulse duration, 60 V 
intensity with train durations of 300 ms. Focal stimulation following co-application of MRS 
2179 (10 µM) and NLA (100 µM) to block inhibitory myenteric neuron signaling abolished 
inhibitory junction potentials and unmasked excitatory junction potentials. All membrane 
potential recordings were obtained using a Multiclamp 700b amplifier (Molecular devices, 
San Jose, CA), a Digidata 1550B analog-to-digital signal converter (Molecular devices, 
San Jose, CA), and Axoscope 11.1 software (Molecular Devices, San Jose, CA). The 
amplified signal was sampled at 2 kHz and filtered at 1 kHz. Successful impalements of 
a circular smooth muscle cell were determined by a rapid drop in the resting membrane 
potential, and only cells that sustained a resting membrane potential bellow -40 mV were 
considered for statistical analysis. Mean average values were determined by averaging 




Dissected distal colon tissue was pinned to a Sylguard silicone-coated petri dish with 
mucosa facing up and fixed overnight in 4% paraformaldehyde at 4°C. The tissue was 
then washed 3 times for 10 minutes with 0.1M phosphate buffer (PB) solution. The 
mucosa and submucosal plexus were then removed by microdissection, leaving the 
circular and longitudinal muscle layers and myenteric plexus. Tissues from two mice of 
same age and genotype were pooled and placed in guanidine thiocyanate lysis-
containing buffer, homogenized mechanically with a tissue homogenizer, lysed through a 
sterile, 22-gauge hypodermic needle, and ultrasonically sonicated before RNA isolation.  
RNA was isolated from the distal colon samples using the Qiagen RNeasy Fibrous Tissue 
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Mini kit according to the manufacturer’s instructions. Isolated RNA was analyzed on a 
NanoDrop One Spectrophotometer (ThermoFisher Scientific) to ensure adequate 
concentration and purity and then stored at -80°C until use. cDNA was generated from 
0.5 μg of RNA using Reverse Transcriptase SuperScript III (RT SS III), random primers 
(Invitrogen), and dNTPs (Invitrogen). Random primers, dNTPs, and RNA were incubated 
at 65°C for 5 minutes. Salt buffers, 0.1M DTT, RNaseOUT, and RT SS III, were added 
and incubated at 25°C for 5 minutes, 50°C for 60 minutes, and then at 70°C for 15 
minutes. cDNA was either kept undiluted or diluted 1:3 in water. Comparative qPCR using 
SYBR Green (Applied Biosystems) and gene-specific primers (Integrated DNA 
Technologies) was performed on a QuantStudio 7 Flex Real-Time PCR System (Applied 
Biosystems). ΔΔCt values were calculated by comparing genes of interest with the 
endogenous control gene GAPDH and normalizing to the WT control condition to 




No more than two measurements were acquired from any one animal for each 
experiment. Data points for each experiment are presented as mean measurement per 
animal ± SEM of mean measurements from all animals. Statistical significance (P value 
less than 0.05) of comparisons between genotypes was determined using 






Scn1b-null mice exhibit colonic dysmotility 
The phenotype of Scn1b-null mice, including spontaneous and generalized seizures as 
well as failure-to-thrive (FTT) by post-natal day (P) 13, ataxia, and premature death 
around ~P17-P19 (Chen et al., 2004; Yuan et al., 2019), mirrors the intractable seizures, 
developmental delay, ataxia, and high risk for sudden unexpected death in epilepsy 
(SUDEP) observed in DEE52 patients (Aeby et al., 2019; Ogiwara et al., 2012; Patino et 
al., 2009; Personal_Communication, 2019 & 2020; Ramadan et al., 2017). Similar to other 
DEE patients (Beck et al., 2021), DEE52 patients are also reported to experience GI 
symptoms, including constipation (Personal_Communication, 2019 & 2020). To 
determine if Scn1b-null mice also exhibit constipation, we recorded pairs of null and wild-
type (WT) littermates in observation chambers for a period of 35 minutes. Despite 
significantly increased feeding behavior (P = 0.015; Figure 3.1A), Scn1b-null mice 
exhibited a reduction in ad libitum defecation events both during (P = 0.0668; Figure 3.1B) 
and outside the time range of the observation period (P = 0.0013; Figure 1C).  To more 
directly test colonic motility, we inserted a glass bead into the distal colon of Scn1b-null 
and WT mice and recorded time to bead expulsion through the rectum. Scn1b-null mice 
exhibited a significant delay in bead expulsion (P = 0.0028; Figure 3.1D), further 
confirming the constipation phenotype in these animals. Because the Scn1b-null 
phenotype includes FTT, predicting potential deficits in nutrient absorption, we proposed 
that a reduction in colonic smooth muscle may contribute to the colonic dysmotility; 
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however, we observed no differences in multiple metrics of musculature between Scn1b-
null and WT distal colon cyrosections (Figures 3.1E-1H). 
 
Figure 3.1: Scn1b-null mice exhibit constipation and colonic dysmotility despite 
increased feeding behavior and normal distal colon muscle size. We observe that 
P15+ Scn1b-null mice, despite A) increased time spent feeding during a 35-minute 
observation period (P = 0.015), exhibit decreased ad libitum defecation events B) during 
the defined observation period (P = 0.0668) as well as C) throughout the entire time spent 
in the observation cage (P = 0.0013). D) P15+ Scn1b-null mice took significantly longer 
to expel a 1.5mm bead inserted ~1cm into distal colon (P = 0.0028). E i-ii) this constipation 
phenotype is not due to decreased musculature in P15+ Scn1b-null distal colons 
compared to age-matched WT mice, as measured by F) average smooth muscle 
thickness (P = 0.1122), G) average internal circumference of distal colon segments, and 
H) average cross-sectional area of distal colon muscle sections. Scale bars: 0.5 mm. * = 
P < 0.05, ** = P < 0.01. Data are represented as the mean ± SEM. B,C) Each data point 
represents the cumulative fecal output from two age-matched, genotype-matched 
animals observed in the same cage.   
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Scn1b-null mice have dysregulated neurogenic colonic motility patterns 
Proper colonic motility relies on functional neurotransmission from colonic myenteric 
motor neurons to effector SMCs. Inhibitory motor neurons release nitric oxide (NO) to 
induce smooth muscle relaxation, while excitatory motor neurons induce smooth muscle 
contraction via acetylcholine (ACh) signaling (Furness, 2000; Greig & Cowles, 2017; 
Hansen, 2003; Qu et al., 2008; Schneider et al., 2019). To better understand the 
mechanisms underlying the in vivo colonic dysmotility in Scn1b-null mice, the distal colon 
was dissected from null or WT mice and placed in a temperature-controlled bath of 
oxygenated Krebs solution. The colon was longitudinally stretched to an initial tension of 
0.2 grams, and the resulting motility patterns were recorded in the absence of drugs or in 
the presence of: sodium nitroprusside (SNP; 5 µM), a NO donor that induces a maximum 
relaxation response; bethanechol chloride (10 µM) a SMC ACh receptor agonist that 
induces a maximum contraction response, or tetrodotoxin (TTX, 300 nM), a selective 
VGSC blocker that silences neuronal activity. 
 
We observed no difference in the SNP-induced maximum relaxation responses (Figure 
3.2A), or bethanechol chloride-induced maximum contraction responses (Figure 3.2B) 
between genotypes, indicating that SMCs in Scn1b-null colon are able to function properly 
in response to exogenous inhibitory and simulated excitatory neurotransmission 
paradigms. We applied focal stimulation to Scn1b-null and WT tissues to confirm 
neurogenic relaxation and contraction responses (Figure 3.2Ci/ii). We then analyzed the 
magnitude, frequency, and regularity of contractions in the absence and presence of 300 
nM TTX to specifically block TTX-S VGSCs.  Of note, two Scn1b-null mice, aged P14 and 
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P16, respectively, exhibited no stretch-induced contraction events. In the preparations in 
which we observed a contractile response, we observed no genotypic differences in the 
average magnitude of distension-induced baseline contractions in the absence or 
presence of TTX (Figure 3.2E,G), suggesting that Scn1b-null smooth muscle contractility 
is intact and unaffected by TTX addition. We further validated that the chosen TTX 
concentration was specifically blocking endogenous neurogenic signaling to SMCs by 
repeatedly performing focal stimulation (at the same intensities at applied in Figure 3.2C) 
and observing no immediate relaxation or contraction responses. Though baseline 
contraction magnitude was no different between Scn1b-null and WT mice, we observed 
substantial age-dependent differences in contraction frequency and regularity the Scn1b-
null animals compared to WTs. Scn1b-null mice aged P15 - P16 showed a significant 
reduction in the average number of contractions per minute compared to P14-P16 WTs 
under baseline conditions (P = 0.0036; Figure 3.2Di/ii, E). This aberrant Scn1b-null 
contraction frequency was abolished following perfusion of TTX (P = 0.0104; Figure 3.2D 
iii/iv, H), suggesting that aberrant activity of Scn1b-null myenteric neurons underlies the 
observed reduction in contraction events compared to WT animals. P15+ Scn1b-null mice 
also exhibited significantly increased time between individual contraction events [or inter-
spike intervals (ISIs)] (P = 0.0176; Figure 3.2Di/ii, I) as well as significantly increased 
standard deviation (SD) of these ISIs (P = 0.0289; Figure 3.2Di/ii, J). Both of these 
genotype-specific differences were ablated in the presence of TTX (Figure 3.2Fii/ii, I, J), 
once again suggesting aberrant enteric neuronal activity was driving the irregular 
contraction patterns. Both WT and Scn1b-null tissues stimulated before TTX addition to 
establish baseline neuronally mediated contraction capacity, were repeatedly stimulated 
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under TTX conditions to verify that neurons were not active (Diii,iv), and stimulated again 
after TTX was washed from the system to verify that the neurons regained normal 
excitability. The P16 Scn1b-null animal that showed no contraction events at baseline 
also exhibited no contractions under TTX conditions, but this animal did exhibit 
contractions in response to focal stimulations both before TTX perfusion and after TTX 
wash. The P14 Scn1b-null animal that showed no contraction events at baseline, did 
exhibit contractions in the presence of TTX as well as in response to focal stimulations 
before and after TTX administration. Strikingly, none of these observed differences in 
baseline contraction frequency and/or regularity were observed in P14 Scn1b-null 
animals, which did not differ from P14-P16 WTs in contractions per minute (Figure 3.2K), 
ISI (Figure 3.2L), or ISI SD measures (Figure 3.2M). Taken together, these data show 
that Scn1b-null mice have reduced and irregular colonic contraction patterns that are 





Figure 3.2: Scn1b-null mice have normal contraction and relaxation amplitudes in 
distal colon but exhibit age-associated diminished and irregular neuronally 
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stretched segments of distal colon. We observed no difference in the relative responses 
to A) exogenous inhibitory neurotransmission or B) simulated excitatory 
neurotransmission. C) Focal stimulation (black arrows) induced neurogenic relaxation 
and contraction responses in both Scn1b-null and WT animals. (Fi/ii) Addition of 300nM 
TTX blocked neurogenic responses to focal stimulation (black arrows). (E,G) While there 
was no difference in mean distension-induced peristaltic contraction magnitude between 
genotypes in either baseline or TTX conditions, we did observe differences in baseline 
contractility patterns between WT (Di) and Scn1b-null (Dii) mice. P15+ Scn1b-null exhibit 
H) significantly decreased baseline contraction frequency (P = 0.0036) as well as I) 
significantly increased time between contractions [ISIs] (P = 0.0104) and J) standard 
deviation of ISIs (P = 0.0289). All of these genotype-dependent differences were 
abolished when neuronal activity was blocked in the presence of TTX (Fi/ii,H, I, J). P14 
Scn1b-null animals exhibited no difference from P14-P16 WT contractility patterns in the 
baseline or TTX conditions (K-M). * = P < 0.05, ** = P < 0.01. Data are represented as 





Scn1b-null mice show age-associated alterations in VGIC-encoding gene expression 
Recent work has shown that the cleaved intracellular domain of the b1 subunit can 
translocate to the nucleus where it regulates transcription of VGSC and other VGIC genes 
(Bouza et al., 2021). Scn1b-null mice exhibit altered protein and gene expression of 
VGICs in brain, spinal cord, and heart (Bouza et al., 2021; Brackenbury et al., 2010; Chen 
et al., 2004; Lin et al., 2015; Lopez-Santiago et al., 2011; Lopez-Santiago et al., 2007). 
Multiple types of VGICs are expressed in the mammalian ENS and GI tract. The VGSCs 
Nav1.5 (Scn5a) and Nav1.9 (Scn11a) are thought to be important in enteric neuron and 
SMC excitability (Copel et al., 2013; O'Donnell et al., 2016; Osorio et al., 2014; Padilla et 
al., 2007). Voltage-gated calcium channels (VGCCs), specifically Cav2.2 (Cacna1b) and 
Cav2.3 (Cacna1e), are thought to control neurotransmitter release of ACh and NO, 
respectively (Bian et al., 2004; Bridgewater et al., 1995; E. Rodriguez-Tapia, Perez-
Medina, Bian, & Galligan, 2016; E. S. Rodriguez-Tapia et al., 2017; Rugiero et al., 2002; 
Shuttleworth & Smith, 1999; Smith et al., 2003; Vogalis et al., 2002; Wessler et al., 1990). 
We dissected distal colon sections containing longitudinal muscle, circular muscle, and 
myenteric plexus from age-matched P14 and P16 Scn1b-null and WT mice. We then 
isolated RNA from these samples and performed qRT-PCR to determine whether 
differences in VGIC gene expression may explain the colonic dysmotility observed in 
P15+ Scn1b-null animals. We observed significant increases in the expression of Scn9a 
(P = 0.0041; Figure 3.3A) and Scn11a (P = 0.0058; Figure 3.3A) in P16 Scn1b-null 
compared to P16 WT samples. Additionally, we observed significant decreases in the 
VGCC genes Cacna1b (P = 0.0026; Figure 3.3B) and Cacna1e (P = 0.0135; Figure 3.3B) 
in P16 Scn1b-null animals compared to age-matched controls. In contrast, we observed 
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no significant differences in the relative expression of any VGIC genes in the P14 Scn1b-





Figure 3.3: Scn1b-null mice exhibit age-dependent altered expression of VGSC and 
VGCC-encoding genes. RT-qPCR performed on smooth muscle + myenteric plexus 
preparations from P14 and P16 Scn1b-null and WT mice reveal A) increased expression 
of VGSC-encoding genes, Scn9a (P = 0.0041)  and Scn11a (P = 0.0058), and B) 
decreased expression of VGCC-encoding genes, Cacna1b (P = 0.0026) and Cacna1e (P 
= 0.0135), in P16 Scn1b-null animals. C, D) None of these changes in VGIC gene 
expression – including Scn9a (P = 0.1004) – are observed in  P14 Scn1b-null animals.  * 
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Scn1b-null mice have normal density, size, and ratios of myenteric motor neurons  
Altered SCN1B/Scn1b expression has been linked to deficits in enteric neuron expression 
in human colon (O'Donnell et al., 2019) as well as aberrant neuronal migration and 
proliferation in mouse CNS (Brackenbury et al., 2013). Therefore, we investigated 
whether P14 (black) and/or P15+ (red) (Figure 3.4) Scn1b-null mice had normal numbers 
and somal sizes of excitatory and inhibitory myenteric neurons in distal colon, as altered 
myenteric motor neuron density or development of excitatory and/or inhibitory enteric 
myenteric motor neuron populations may contribute to the observed colonic dysmotility. 
To image myenteric neurons, we extracted distal colon from age-matched Scn1b-null and 
WT ChAT-eGFP mice, in which the enzyme choline acetyltransferase (ChAT), which 
synthesizes the primary excitatory enteric neurotransmitter ACh, is labeled with an 
endogenous GFP tag. After the colons were dissected, we stripped away the mucosa, 
submucosa, and circular muscle layers to reveal the myenteric plexus. These LMMPs 
were then immunostained with antibodies against ANNA-1 (HuC/D antisera), which labels 
both excitatory and inhibitory enteric neurons (Kulkarni et al., 2017), as well as neuronal 
nitric oxide synthase (nNOS), which labels inhibitory enteric neurons. We observed 
normal neuronal and ganglionic densities (Figures 3.4C ,3.4D) as well as normal mean 
neuron size (Figure 3.4E) in the distal colons of Scn1b-null animals. We then analyzed 
the subpopulations of excitatory (ChAT+) and inhibitory (nNOS+) enteric neurons and 
observed no differences between genotypes in excitatory neuron proportion or mean size 
(Figures 3.4F, 3.4G) or inhibitory neuron proportion or mean size (Figures 3.4H ,3.4I). 
Furthermore, there were no age-related differences within the Scn1b-null population 
across any metric of myenteric neuron density, size, or excitatory/inhibitory ratios. These 
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data suggest that the observed dysmotility in P15+ Scn1b-null animals is not caused by 








Figure 3.4. Scn1b-null mice have normal quantities, size, and proportions of 
myenteric neuron subtypes and ganglia. A, B) Representative images taken of 
myenteric plexus in P14-P16 Scn1b-null and WT distal colons revealed C, D) no age- or 
genotype-dependent differences in myenteric neuron density, myenteric ganglion density, 
or average myenteric neuron size. Subsequent analysis of the two major subpopulations 
of myenteric neurons revealed no difference in size or ratio of F, G) excitatory (ChAT+) 
myenteric neurons or H, I) inhibitory (nNOS+) myenteric neurons.  Scale bars: 50 µm. 
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Scn1b-null mice have altered myenteric plexus connectivity  
Previous studies have shown that b1 subunits promote neurite outgrowth in CNS neurons 
(Davis et al., 2004; McEwen & Isom, 2004; Patino et al., 2011). These small immature 
extensions establish polarity, develop into axons and dendrites, and begin to form mature 
neural circuits. In the brain and spinal cord, b1 subunits also mediate axon fasciculation, 
the process by which growing axons adhere to one another to limit the dispersion of 
axonal tracks and generate more precise connections (Brackenbury et al., 2013). Proper 
excitatory and inhibitory connections within the myenteric plexus are necessary for highly 
stereotyped and coordinated motility patterns, and small changes in the organization of 
the plexus can produce large alterations in GI function (Sasselli et al., 2013). Therefore, 
we next sought to determine if Scn1b-null mice have normal axonal connections between 
myenteric ganglia in colon. Using anti-TUJ1 immunostaining to visualize axonal 
connections within the myenteric plexus of P14-P16 Scn1b-null and WT animals, we 
observed no difference in the average density of axonal connections between myenteric 
ganglia as well as no difference in the average length or width of the axonal bundles in 
Scn1b-null mice compared to WTs across all tested ages (Figure 3.5C-E). Each axon 
bundle in Scn1b-null and WT animals consisted of both excitatory (ChAT-eGFP+) and 
inhibitory (nNOS+) axons (Figures 3.5F, 3.5G). These data suggest loss of b1 subunits 




Figure 3.5: Scn1b-null mice exhibit normal inter-ganglionic axonal connections 
within the myenteric plexus. A, B) Representative images taken of myenteric plexus 
connections in P14-P16 Scn1b-null and WT distal colons revealed no difference in C) 
average density of axonal bundles connecting myenteric ganglia as well as D) no 
difference in average bundle length or E) width. F, G) Representative images showing 
axon bundles in P14-P16 Scn1b-null and WT distal colon contain both ChAT+ and nNOS+ 
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Scn1b-null mice exhibit normal SMC responses to myenteric neuronal signaling  
Our data suggest that the distal colons of P15+ Scn1b-null animals have dysregulated 
distension-induced peristatic contractions as well as aberrant expression of genes 
encoding VGICs necessary for myenteric neuron excitability and neurotransmitter release 
compared to WT animals. However, there were no evident differences in myenteric 
neuronal density or subpopulation ratios in distal colon between the two genotypes. 
Furthermore, Scn1b-null animals exhibited intact, properly sized, though slightly 
increased, axonal connections between myenteric ganglia. These results suggest that the 
mechanism of colonic dysmotility in Scn1b-null animals may include aberrant stimulus-
induced inhibitory and/or excitatory signaling between myenteric neurons and SMCs. In 
mammals, proper inhibitory and excitatory myenteric neuron signaling to circular SMCs, 
but not longitudinal SMCs, in distal colon is necessary for distension-induced peristalsis 
(Spencer, Dickson, Hennig, & Smith, 2006). To test the integrity of signaling from 
myenteric neurons to circular SMCs in P15+ Scn1b-null animals, we performed sharp-
electrode electrophysiological recordings in the distal colons of P15+ Scn1b-null and P14-
P16 WT animals. We dissected distal colon sections containing longitudinal muscle, 
circular muscle, and myenteric plexus from these animals, and the circular SMCs were 
impaled with an intracellular microelectrode to record membrane potential. We then 
stimulated myenteric neurons in the tissue preparation using transmural electric field 
stimulation (EFS). Previous pharmacological studies show this stimulation intensity is 
below the threshold required to directly stimulate SMCs, so any observed changes in 
SMC membrane depolarization (inhibitory junction potential) or hyperpolarization 
(excitatory junction potential) following the stimulation was due to neuronal signaling to 
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SMCs (Perez-Medina & Galligan, 2019). Under baseline conditions, we observed no 
difference between the Scn1b-null and WT resting membrane potential (Figure 3.6B). 
Furthermore, we observed no difference in inhibitory junction potential size between P15+ 
Scn1b-null and P14-P16 WT animals in response to EFS (Figures 3.6Ai/ii, C, D). 
Likewise, we observed no difference in resting membrane potential nor in the relative 
reduction in inhibitory junction potential size under TTX conditions (Figures 3.6Ei/ii, F-H). 
Finally, we applied MRS 2179 and Nitro-L-Arginine (NLA) to block inhibitory junction 
potentials and unmask the excitatory junction potential response to EFS. Again, we 
observed no difference in resting membrane potential of Scn1b-null and WT SMCs under 
these conditions (Figure 3.6J). As with inhibitory signaling, we observed no difference in 
myenteric neuron excitatory signaling to SMCs between genotypes (Figures 3. 6Gi/ii, H, 
I). These data suggest that both inhibitory and excitatory myenteric neuron populations 
are able to signal properly to SMCs in response to electrical stimulation in P15+ Scn1b-





Figure 3.6: Scn1b-null mice exhibit no deficits in electrical stimulation-induced 
inhibitory or excitatory myenteric neuronal signaling to smooth muscle cells. 
Electrophysiological recordings from smooth muscle cells in P15+ Scn1b-null and P14-
Inhibitory junction potential (IJP) 
Excitatory junction potential (EJP)
= P14 and younger





















































































































































































































P16 WT distal colon reveal reduction in A,C,D) inhibitory or I, K, L) excitatory signaling 
from myenteric neurons in response to electrical field stimulation (EFS). E,G,H) 
Additionally, there was no difference between genotypes in myenteric response to EFS 
in the presence of 300 nM TTX.  Finally, there was no difference in SMC resting 
membrane potential between genotypes in any recording condition (B,F,J) Data are 






This project investigated a potential mechanism, aberrant activity of VGSC b1/b1B, that 
may underlie GI dysmotility symptoms commonly experienced by DEE patients with 
variants in SCN1B (DEE52). Based on the established roles of VGSC b1/b1B subunits in 
CNS activity and development, we also sought to determine if b1/b1B subunits played 
analogous parts in the ENS. Our data suggest that P15+ Scn1b-null mice mirror the 
constipation phenotype observed in DEE52 and other DEE channelopathy patients – and 
that this colonic dysmotility is driven by reduced and dysregulated peristaltic contractions 
within distal colon. Due to the absence of genotype-specific differences in the presence 
of TTX, we postulate that changes in neuronal excitability are responsible for the 
observed contractile dysfunction. Furthermore, our data suggest that differential mRNA 
abundance of VGSC and VGCC genes, which are necessary for proper enteric neuron 
excitability and signaling to effector SMCs, might contribute to the mechanism of 
dysmotility in Scn1b-null colon.  
 
The observed colonic dysmotility phenotype appears to be developmentally regulated in 
the Scn1b-null model of DEE52: P14 Scn1b-null mice exhibit neither the colonic 
dysmotility patterns nor the altered gene transcription profiles found in P15+ Scn1b-null 
mice. As Scn1b-null animals age, they develop CNS hyperexcitability and FTT (Chen et 
al., 2004; Yuan et al., 2019). Scn1b-null animals exhibit more severe dysfunction that 
correlates with their disease onset by ~P12, disease progression, and eventual death by 





We observed aberrant expression of the VGIC-encoding genes Scn9a, Scn11a, 
Cacna1b, and Cacna1e in the distal colon of Scn1b-null mice. Many of these genes – as 
well as their respective protein products – are also found to be differentially expressed in 
Scn1b-null CNS, heart, or other subsets of PNS (Bouza et al., 2021; Lopez-Santiago et 
al., 2011). While the proteins encoded by Scn11a, Cacna1b, and Cacna1e have 
established roles in myenteric neuron signaling and GI smooth muscle motility (Bian et 
al., 2004; Copel et al., 2013; Osorio et al., 2014; Rugiero et al., 2002; Shuttleworth & 
Smith, 1999; Smith et al., 2003; Vogalis et al., 2002; Wessler et al., 1990), the protein 
product of Scn9a (Nav1.7) does not yet have a known function in the GI system – though 
other researchers have reported Scn9a gene or Nav1.7 protein expression in the GI tract 
of laboratory animals (Bartoo et al., 2005; Sage et al., 2007) and humans (Hetz et al., 
2014). Unlike Nav1.5 and Nav1.9 (encoded by Scn5a and Scn11a, respectively), Nav1.7 
is a TTX-sensitive VGSC. Based on the effects of nanomolar TTX on enteric neuron 
action potential generation as well as patterns of colonic motility, there is substantial 
evidence for TTX-sensitive VGSC a subunit involvement in proper GI motility; however, 
the molecular identities of the TTX-sensitive VGSC(s) contributing to these activities are 
unknown (Fida et al., 1997; G. D. Hirst et al., 1974; Nakagawa et al., 2005). The significant 
upregulation of Scn9a in P15+ Scn1b-null mice may indicate the involvement of Nav1.7 
in regulated colonic contraction and relaxation patterns. Alternatively, this genetic 
upregulation could be compensatory to counter reductions in other VGIC activity in the 
Scn1b-null colon. Evidence of the latter scenario has previously been proposed in mice 
lacking Cacna1a (encoding the P/Q-type VGCC Cav2.1), which exhibit an enhancement 
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in the function of L-type VGCCs to maintain normal myenteric neuron inhibitory signaling 
(E. Rodriguez-Tapia et al., 2016).  
 
We observed normal inhibitory and excitatory responses to electrical field stimulation in 
Scn1b-null SMCs. Though myenteric neuron signaling to circular smooth muscle is 
reportedly necessary and sufficient for distension-induced motility patterns (Spencer et 
al., 2006), it is possible that electrical stimulation bypasses dysfunctional 
mechanosensitive neuronal populations or induces firing in normally hypoexcitable 
myenteric neurons in the Scn1b-null model. Likewise, our baseline contraction amplitude 
data (Figure 3.2 C) taken with the measures of contraction regularity (Figures 3.2 E-G) 
show that – while stimulus-induced myenteric neuronal signaling to SMCs is just as robust 
in Scn1b-null mice as in WT mice when it occurs – this signaling is less frequent and less 
regular in Scn1b-null than in WTs. Both TTX-R and TTX-S VGSCs are also expressed in 
SMCs (Alberti et al., 2007; Berra-Romani, Blaustein, & Matteson, 2005; Beyder & 
Farrugia, 2012; Hetz et al., 2014; Holm et al., 2002; Neshatian et al., 2015; O'Donnell et 
al., 2016; Ou et al., 2002; Strege et al., 2007); however, we observe normal myogenic 
distension-induced contractions as well as resting membrane potential in SMCs in both 
baseline and TTX conditions, suggesting that intrinsic colonic smooth muscle excitability 
and contractility is unaffected in Scn1b-null animals. Due to the complex interplay of 
smooth muscle contractions and relaxations that produce highly stereotyped patterns of 
colonic motility, it is difficult to determine whether this observed dysmotility is due to 
aberrant excitatory signaling, inhibitory signaling, or both. A reduction in defined 
contractions could be due to a relative decrease in excitatory signaling events, an 
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unbalanced increase in basal inhibitory or excitatory tone, or even a reduction in inhibitory 
signaling events, resulting in depolarization block of SMCs such that they cannot produce 
contractions in response to excitatory neurotransmission. To more directly address the 
mechanisms underlying the observed colonic dysmotility in Scn1b-null mice, future work 
will need to examine individual excitatory and inhibitory myenteric neuron excitability in 
Scn1b-null and WT distal colon via whole-cell patch clamp experiments.  
 
In conclusion, this work supports the idea that GI symptoms in channelopathies such as 
DEE may be caused by expression of the particular ion channel gene variant in ENS 
neurons, resulting in aberrant motility and functionality of the GI tract. Furthermore, our 
data suggest that SCN1B has analogous roles in the CNS and ENS – impacting neuronal 
excitability, VGIC gene expression, and network connectivity. 
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While the primary focus of this thesis has been to understand the role of Scn1b in 
myenteric neurons, pacemaker cells, and SMCs of the distal colon, it is important to 
remember that the GI system contains myriad cell types – many of which are also known 
to express VGSCs. It is therefore logical that aberrant VGSC expression or function due 
to SCN1B disease variants could impact other functions vital to normal GI function. In this 
final chapter, I will elaborate on some potential additional roles of VGSC b1/b1B subunits 
in the GI system – including preliminary data from our laboratory – as well as some 
potential avenues of future GI research in our mouse model of DEE52: 
4.2: DEE52 patients and Scn1b-null mice exhibit severe failure-to-thrive. VGSC b1 
subunits may play a role in proper development, nutrient absorption, and/or 
motility of the small intestine. 
4.3: The vagus nerve serves as one of the primary routes of communication between 
the CNS and the GI system. In mice, VGSC b1 subunits are known to be 
expressed at AIS and nodes of Ranvier in the vagus nerve, which enable the 
conduction of nerve signals over long distances. VGSC b1 subunits may play a 
role in the proper functioning of the vagal connection between brain and gut.  
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4.4: The gut microbiome is necessary for proper GI – and potentially CNS – function, 
and its composition can be disrupted in genetic disorders and various epilepsies. 
The gut microbiome may be altered in DEE52 patients and Scn1b-null mice, 
contributing to malabsorption and dysmotility. 
4.5: The ketogenic diet is known to be therapeutic in many forms of epilepsy, including 
DEEs; however, the impact of the diet on longevity and other relevant metrics in 




4.2 Elucidating the Role of Scn1b in Nutrient Absorption and Metabolic Function 
 
 
As discussed in Chapter 1, most of the body’s absorption of macronutrients 
(carbohydrates, proteins, and lipids) and micronutrients (vitamins and minerals) during 
digestion occurs in the small intestine, and this process involves the submucosal plexus 
(Fish & Burns, 2021; Ogobuiro et al., 2021). Luminal stimuli, such as mechanical 
distension or the acid and nutrients in digested food that enters the duodenum from the 
stomach, prompt enterochromaffin cells to release 5-HT and ATP to submucosal afferent 
neurons (Xue, Askwith, Javed, & Cooke, 2007). Activated secretomotor neurons in the 
submucosal plexus release SP, VIP, and ACh - which bind to receptors on epithelial cells 
and stimulate secretions into the intestinal lumen (Furness, 2007; Hansen, 2003; Hansen 
& Skadhauge, 1997; Reed & Vanner, 2001, 2003; Xue et al., 2007). Enterochromaffin 
cells and submucosal neurons express VGSCs (Bartoo et al., 2005; Padilla et al., 2007; 
Strege et al., 2017). Therefore, aberrant VGSC expression or function due to SCN1B 
disease variants could impair nutrient absorption and extraction by impacting the 
excitability of enterochromaffin cells and/or submucosal enteric neurons. 
 
DEE52 patients, as well as patients with DEEs linked to other VGSC gene variants, exhibit 
a striking reduction in developmental growth and weight gain, ie. failure-to-thrive (FTT), 
despite clinical reports of adequate caloric intake (Personal_Communication, 2019 & 
2020) (Table 1.1). Scn1b-null mice also exhibit a FTT phenotype, despite the 
aforementioned observations of constant feeding (Figure 3.1 A, Figure 4.1 A, B) (Chen et 





Figure 4.1: Scn1b-null mice exhibit a failure-to-thrive phenotype. A) P19 Scn1b-null 
mouse compared to a WT littermate.  B) Scn1b-null mice exhibit a marked decrease in 
developmental weight gain, with weights beginning to deviate from age-matched WT 
mice around P12. Picture initially published in Chen et al. (2002); weight data collected 





Aside from the evident FTT observed in Scn1b-null mice, preliminary morphological 
evaluations of the Scn1b-null small intestine suggest potential aberrant nutrient 
absorption capabilities. I observed a relative increase in Scn1b-null small intestine length 
to body weight ratio compared to WT littermates of either the same age or to WTs of 
similar body weight (Figure 4.2 A). This suggests that Scn1b-null animals continue to 
devote energy resources to elongating their GI tract, even after their overall 
developmental weight gain has stagnated around P11 or P12. This relative increase in 
energy allocation may serve as a compensatory mechanism to offset FTT, as a longer 
small intestine would allow for more surface area available for nutrient absorption. Further 
Figure 4.2: Scn1b-null animals exhibit aberrant GI tract morphology. Loss of Scn1b 
results in (A) a higher small-intestine length to body weight ratio and B) a slight 
reduction in average villus height in all three sections of the small intestine. 
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morphological analysis of the small intestine found a reduction in average villus height in 
all three sections (Figure 4.2 B-D), and preliminary data from Scn1b-null mice, performed 
in conjunction with the Adipose Tissue Core within the Michigan Nutrition Obesity Center, 
also suggest defects in lipid absorption (Figure 4.3). These findings suggest that Scn1b-
null animals may exhibit FTT due to defects in macronutrient absorption through their 
intestinal villi.  
 
Results of the Oil Red O staining experiment (results shown in Figure 4.3) could be 
verified in future work by performing the same analysis on fecal smear samples from 
Scn1b-null and WT mice. If fecal smears from null -mice show a larger lipid accumulation, 
it would further support the idea that Scn1b-null mice have aberrant intestinal lipid 
absorption rather than deficits in dietary lipid intake. Future experiments could also 
investigate relative caloric absorption within the GI tract of Scn1b-null and WT mice by 
performing bomb calorimetry on fecal samples in partnership with the University of 
Michigan Nutrition Obesity Center’s Animal Phenotyping Core. These latter experiments 
would enable us to understand general macronutrient absorption in the intestines of 




Figure 4.3: Scn1b-null mice exhibit evidence of macronutrient malabsorption. 
Scn1b-null mice (F-J) exhibit decreased intestinal lipid accumulation (shown by Oil Red 




We performed metabolic analyses in conjunction with the University of Michigan Small 
Animal Phenotyping Core, including NMR spectroscopy to provide information on the 
chemical structure of Scn1b-null and age-matched WT tissues (Figure 4.4 A-C). These 
experiments were performed at two ages: P10, which is prior to the onset of the FTT 
phenotype in Scn1b-null mice, and P15, at which point the weights of Scn1b-null mice 
and their WT littermates have begun to deviate significantly. These data suggest that 
Scn1b-null mice exhibit an age-dependent decrease in proportion of lean tissue, such as 
skeletal muscle, which could result from the improper absorption or cellular uptake of 
macronutrients such as proteins. We were surprised to see that, at both ages, Scn1b-null 
mice exhibited a larger percentage of fat tissue mass compared to their overall body 
mass. Anecdotal evidence from numerous dissections from these animals suggested a 
visible reduction in white adipose tissue surrounding the internal organs of Scn1b-null 
mice. To begin to address this apparent discrepancy, further research could probe 
potential differences in location of fat accumulation as well as precise differences in fatty 
tissue composition/metabolic activity between Scn1b-null and WT animals. 
 
 
Figure 4.4: Scn1b-null mice exhibit aberrant body tissue composition, as 
measured by NMR. Scn1b-null mice exhibit age-dependent and genotype-dependent 





Finally, it is possible that Scn1b plays a similar role within the myenteric neuron population 
in the small intestine as it does in the large intestine – facilitating the intricate motility 
patterns that are necessary for proper digestion. Migrating motor complexes and 
peristalsis also occur in the small intestine, and organ bath experiments – similar to those 
discussed in Chapter 3 – could compare the contraction patterns of duodenum, jejunum, 
and ileum segments from Scn1b-null and WT animals. Furthermore, we could measure 
GI motility by comparing the rate of gastric emptying in age-matched Scn1b-null and WT 
mice. Mice would be administered an oral gavage of a non-nutrient dye, and intestinal 
transit would be assessed at a set time point after gavage. Aberrant small intestine motility 
patterns and transit times could produce the FTT phenotype; increased rates of intestinal 
motility could shunt digested material through the small intestine too quickly to be 
effectively absorbed, while decreased rates of intestinal motility could lead to bacterial 
overgrowth (SIBO) – leading to malabsorption (Dukowicz, Lacy, & Levine, 2007; Keller & 
Layer, 2014).     
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4.3 Investigating the Function of Scn1b in Gut-Brain Communication 
 
While the ENS can control many GI functions in isolation, the digestive tract relies on dual 
innervation from the ENS and CNS, as well as communication between these two 
nervous systems, for normal physiological functioning (Gershon, 1999). The most direct 
route of contact between the GI tract and the CNS is the vagus nerve. Vagal efferent 
fibers, originating from neurons in the dorsal motor nucleus of the vagus (DMV), help to 
regulate esophageal propulsion, gastric emptying, contractile activity (via complexes with 
myenteric motor neurons, ICCs, and SMCs), and acid secretion (Masuda, Tomita, Okubo, 
& Miyasaka, 1994; Patino & Isom, 2010; Powley & Phillips, 2011). Vagal afferent fibers 
relay information to the CNS regarding GI tract distension as well as the presence of 
hormones and macronutrients within the tract, leading to regulation of hunger and satiety 
sensations (Furness et al., 2014; Masuda et al., 1994; Powley & Phillips, 2011).  
 
Scn1b-null mice have significantly fewer nodes of Ranvier in the optic nerve with 
functional deficits in optic nerve conduction (Chen et al., 2004). Preliminary work shows 
a similar significant reduction in nodes of Ranvier in Scn1b-null corpus collosum 
compared to WT (P = 0.0357; Figure 4.5). The vagus nerve expresses VGSC a and b1 
subunits at nodes of Ranvier (Figure 4.6), thus loss of b1 subunits may impair conduction 
of neural signals along the vagus nerve, reducing vagal input to enteric neurons and 





Figure 4.5: P17 Scn1b-null mice exhibit a significant reduction (P = 0.0357) in 
nodes of Ranvier density in the corpus callosum compared to age-matched WTs. 
Scale bars = 10µm. * = P < 0.05 .Data courtesy of A. De La Rocha. 
 
 
Figure 4.6: Mouse vagus nerve expresses VGSC b and a subunits.  A) b1 subunits 
(green) at nodes of Ranvier (anti-Caspr antibody, blue) and flanked by Kv 1.2 channels 
(red). B,C) a subunits (green) at nodes of Ranvier (anti-Caspr, red). Scale bar = 10µm. 
Data courtesy of Dr. H.A. O’Malley. 
 
The vagus nerve innervates multiple GI targets, suggesting there are precise 
mechanisms that guide vagal axons to establish ENS-CNS innervation patterns. As 
previously discussed, b1/b1B  subunits are CAMs that regulate cell adhesion and 
neuronal migration/axonal pathfinding (Brackenbury & Isom, 2011). Previous studies 
have revealed that both b1 and its soluble splice variant, b1B, promote neurite outgrowth 




associated non-receptor tyrosine kinase fyn signaling pathway following trans homophilic 
cell-cell adhesion (Davis et al., 2004; McEwen & Isom, 2004). The small neurite 
extensions that protrude from immature neurons establish polarity, develop into axons 
and dendrites, and begin to form the connections that eventually define neural circuits. In 
the CNS, Scn1b mediates axon fasciculation, the process by which growing axons adhere 
to one another to limit the dispersion of axonal tracks and generate more precise 
connections between regions. Scn1b-null mice, which lack b1/b1B-mediated neuronal 
outgrowth, exhibit disrupted axonal pathfinding in the cerebellum as well as in the 
corticospinal tract (Brackenbury et al., 2008). Therefore, we predict that Scn1b-null mice 
might also have impaired pathfinding of vagal nerve fibers. 
 
Previous research has suggested that brain-derived neurotrophic factor (BDNF) plays a 
critical role in vagal innervation. BDNF, which is expressed during gut development in 
tissues adjacent to sensory and motor vagal innervation, has been shown to play a role 
in vagal axon growth, guidance, or fasciculation — as mice lacking BDNF display aberrant 
patterning of axon bundles in the gastric antrum (Murphy & Fox, 2010). Fyn kinase, which 
is necessary for b1-mediated neurite outgrowth in the CNS, is responsible for regulating 
BDNF receptor (TrkB) localization in lipid rafts and subsequent signaling in neurons 
(Pereira & Chao, 2007).  Fyn kinase is also known to modulate the activity of VGSCs in 
response to BDNF signaling (Ahn, Beacham, Westenbroek, Scheuer, & Catterall, 2007). 
Loss of b1/b1B subunit function could therefore impair the formation of these complex 
innervation patterns, which are necessary for normal functioning of the CNS, ENS, and 
GI tract. However, whether b1/b1B subunits also mediate axonal tract development and 
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conduction in the nerve tracts between CNS and ENS, and therefore the extent to which 
Scn1b-null disease variants may affect the normal vagal innervation of and transmission 
to the GI tract, has yet to be investigated. 
 
Future studies could therefore examine the effect of Scn1b deletion on vagal development 
and conduction. By dissecting vagus nerves from age-matched Scn1b-null and WT mice 
and then utilizing immunohistochemistry and confocal imaging to quantify changes in 
axonal organization, localization and expression levels of different VGSC a subunits, 
potassium channels, and CAMs, as well as numbers of nodes of Ranvier, we could 
characterize differences in vagus nerve development and fasciculation between 
genotypes. Future work could also assess genotypic differences INa density and 
conduction velocity in the vagus nerve. Another line of investigation could seek to 
establish the effect of Scn1b deletion on the extent and patterning of vagal innervation of 
the stomach and GI tract. Using Scn1b-null and WT mice expressing the fluorescent 
protein tdTomato driven by the Phox2b promoter, which is expressed by mammalian DMV 
neurons (Kang et al., 2007), points of DMV innervation on stomach and intestine could 





4.4 Establishing the Gut Microbiome Profile of Scn1b-null Mice 
 
 
The gut microbiome is involved in several vital functions, including maintenance of GI 
tract motility as well as the synthesis and metabolism of nutrients, vitamins, and drugs 
(Dieterich, Schink, & Zopf, 2018; Quigley, 2011; Rowland et al., 2018; Sun, Chen, & Shen, 
2019). Though infants receive their initial microbiome from their mothers, compositions of 
gut microbiota change with age, and overall heritability of the gut microbiome is very low 
(Backhed et al., 2015; Stanislawski et al., 2017; Turnbaugh et al., 2009; H. X. Wang & 
Wang, 2016). Multiple factors have been found to impact the distribution and diversity of 
species in the gut microbiome, including infections, stress, antibiotics, and chronic 
constipation (Azad, Bridgman, Becker, & Kozyrskyj, 2014; Galley et al., 2014; Ohkusa, 
Koido, Nishikawa, & Sato, 2019). Certain genetic variants are also linked to microbiome 
alterations in humans, including variants that alter the function of genes encoding ion 
channels (Hall, Tolonen, & Xavier, 2017). Cystic fibrosis, a channelopathy caused by 
variants in the gene encoding the cystic fibrosis transmembrane conductance regulator, 
is associated with altered intestinal microbiota (Fiorotto & Strazzabosco, 2019). 
Nonetheless, diet is the most important determinant of gut microbiota composition (Azad 
et al., 2014; Hooper et al., 2001).  
 
Recent studies have suggested that the connection between the gut microbiome and the 
brain might be relevant for neurological disease. Around 25% of autistic patients have at 
least one type of GI disease, and these patients have been reported to exhibit altered 
microbiome compositions by multiple studies (Morais, Schreiber, & Mazmanian, 2021). 
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There is also evidence of associations between aberrant microbiota compositions in 
patients with multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, as well as 
anxiety, depression, and stress (Dieterich et al., 2018; Mazurek et al., 2013; Morais et al., 
2021; X. Zhu et al., 2017).  
 
Finally, there is some evidence supporting microbiome involvement in epilepsy. A few 
human studies have found differences in the fecal microbiota of refractory epilepsy 
patients compared to their healthy peers (Lindefeldt et al., 2019; Lum, Olson, & Hsiao, 
2020; Peng et al., 2018; Xie et al., 2017). There is even a potential difference in the 
microbiome composition between patients with drug-resistant and drug-sensitive epilepsy 
(Dahlin & Prast-Nielsen, 2019; Peng et al., 2018). Fecal transplants, probiotic, and 
antibiotic treatments have been recorded to have anticonvulsant effects (Braakman & van 
Ingen, 2018; Dahlin & Prast-Nielsen, 2019; Gomez-Eguilaz, Ramon-Trapero, Perez-
Martinez, & Blanco, 2018; He et al., 2017). Future studies could examine the fecal 
microbiome of Scn1b-null mice compared to their WT littermates before and after seizure 
onset and developmental weight gain deviation around P12. Furthermore, it would be 
enlightening to perform functional GI motility experiments on the mice (such as those 
described in Chapter 3) following fecal microbiome analysis to determine if any alterations 





4.5 Determining Effect of Ketogenic Diet Intervention on Scn1b-null Mice 
 
 
Based on the knowledge that the microbiome both influences neuronal function and is 
involved in numerous CNS disorders, it is reasonable to infer that changes in diet may 
serve as therapies in the treatment of disease. Studies have revealed that regular 
consumption of certain macronutrients can affect the prevalence of specific bacterial 
phyla in the microbiome (Lindefeldt et al., 2019; G. D. Wu et al., 2011). A common 
alternative treatment for intractable epilepsy patients, including DEE patients, is the high-
fat, low-carbohydrate ketogenic diet (KD). Fasting has been used as form of treatment for 
epilepsy since the time of Hippocrates in 5th century BC, and the KD was first formulated 
in 1921 to induce the metabolic effects of fasting for the management of seizures 
(Caraballo et al., 2005). Use of the KD induces ketosis, in which dietary fat is converted 
to ketone bodies (b-hydroxybutyrate, acetoacetate, and acetone) in the liver as an 
alternative energy source to carbohydrates (Dahlin & Prast-Nielsen, 2019). The resulting 
metabolic alterations are thought to produce neuroprotective effects. In multiple studies, 
this diet-based therapy has been found to both reduce the frequency of a wide range of 
seizure types as well as produce improvements in cognition and behavior in DEE patients 
(Caraballo et al., 2005; Sharma & Tripathi, 2013; Y. Q. Wang, Fang, Zhang, Xie, & Jiang, 
2020). There is also a report of the KD being used successfully in a patient with DEE52 
(Aeby et al., 2019).  
 
It has been proposed that the therapeutic effects of the KD are due to increased inhibitory 
neurotransmitter (GABA) signaling and/or decreased excitatory neurotransmitter 
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(glutamate) signaling, in response to diet-induced changes in intestinal microbiota, 
metabolism, and subsequent neurotransmitter production (Dahlin, Elfving, Ungerstedt, & 
Amark, 2005; Olson et al., 2018; Spinelli & Blackford, 2018; Z. J. Wang et al., 2003; 
Yudkoff et al., 2005). A recent study showed that the ketone bodies b-hydroxybutyrate 
and acetoacetate suppress glutamate release by directly competing with a positive 
allosteric regulator of the vesicular glutamate transporters in neurons (Juge et al., 2010).  
 
It has also been suggested that mitochondria play a vital role in the antiepileptic effects 
of ketone bodies (Rogawski, Loscher, & Rho, 2016). Mitochondria are ATP-producing 
organelles, and reduced levels of ATP production are associated with increased seizure 
susceptibility due to an unstable membrane potential that precedes aberrant neuronal 
firing patterns (Bough et al., 2006; Rogawski et al., 2016). Additionally, clinical studies 
reveal a comorbidity between mitochondrial diseases and epilepsy (Craig, de Menezes, 
& Saneto, 2012). Previous research showed that the KD is associated with a drastic 
upregulation of transcription for genes encoding metabolic enzymes and mitochondrial 
proteins, as well as an increase in mitochondrial biogenesis in the hippocampus—a 
known seizure trigger zone (Bough et al., 2006).  
 
Future experiments could explore the use of this diet in our Scn1b-null mice and allow us 
to better understand the mechanism by which the KD exerts its therapeutic effects in 
DEE52 patients. Because our Scn1b-null mice typically die before P20 and thus do not 
survive past weaning, we could study the effect of the KD in our Scn1b-flox mouse line 
expressing a ubiquitous tamoxifen-inducible Cre (e.g. CMV or ubiquitin). We have shown 
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previously that Scn1bflox/flox/CMV-Cre mice have a phenotype that is indistinguishable 
from Scn1b- null mice (Chen et al., 2004). Scn1bflox/flox mice expressing a Thy1-promoter 
driven, tamoxifen-inducible Cre develop severe seizures and SUDEP within 10 days of 
tamoxifen injection (O'Malley et al., 2019). Therefore, using an inducible line, Scn1b can 
be deleted after the mice are weaned to determine if the KD results in amelioration in 
seizure severity or a reduction in SUDEP occurrence. If an amelioratory effect of the KD 
is observed in our Scn1b-null animals, we can further probe potential diet-mediated 
mechanisms, such as alterations in gene transcription and functional shifts in the animals’ 




4.6 Final Conclusions 
 
Increasing evidence suggests that there is a connection between GI and neurological 
dysfunction in many diseases, including DEEs. The data I have presented in this thesis 
suggest that aberrant function of VGSC a and b1 subunits may provide a mechanism 
for comorbid GI symptoms in DEE patients and other patients with VGSC-linked 
diseases. Specifically, my results support novel roles for Scn1b in the coordination of 
enteric neuron function and colonic motility. Future studies that seek to better 
understand the many roles of VGSC b1 subunits in both normal GI physiology as well 
as the aberrant GI physiology observed in VGSC-linked neurological and GI diseases 
can inform more effective treatments for these patients and improve quality of life for 
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